



江西一脈陽光集團股份有限公司

Jiangxi Rimag Group Co.,Ltd.

(A joint stock company incorporated in the People's Republic of China with limited liability)

Stock Code:2522.HK

2024  
INTERIM REPORT



專注影像 守護健康

# CONTENTS

Corporate Information	2
Financial and Business Highlights	4
Management Discussion and Analysis	6
Corporate Governance and Other Information	31
Condensed Consolidated Interim Income Statement	45
Condensed Consolidated Interim Statement of Comprehensive Income	46
Condensed Consolidated Interim Statements of Financial Position	47
Condensed Consolidated Interim Statements of Changes in Equity	49
Condensed Consolidated Interim Statements of Cash Flows	51
Notes to the Condensed Consolidated Interim Financial Information	52
Definitions	83



## Corporate Information

### BOARD OF DIRECTORS

#### *Executive Directors*

Dr. XU Ke (徐克博士) (*Chairman*)  
Mr. CHEN Zhaoyang (陳朝陽先生)  
Ms. HE Yingfei (何英飛女士)  
Mr. FENG Xie (馮颺先生)

#### *Non-executive Directors*

Mr. LIU Senlin (劉森林先生)  
Mr. MAO Xiaojun (毛曉軍先生)

#### *Independent Non-executive Directors*

Mr. WU Xiaohui (吳曉輝先生)  
Mr. LUO Yi (羅毅先生)  
Mr. YUAN Jun (袁駿先生)

### JOINT COMPANY SECRETARIES

Ms. HE Yingfei (何英飛女士)  
Ms. ZHANG Xiao (張瀟女士)

### AUTHORIZED REPRESENTATIVES

Ms. HE Yingfei (何英飛女士)  
Ms. ZHANG Xiao (張瀟女士)

### SUPERVISORS

Mr. CHEN Guangwei (陳光偉先生) (*Chairman*)  
Mr. XUE Yuansheng (薛源生先生)  
Mr. LIU Weiwei (劉魏偉先生)

### AUDIT COMMITTEE

Mr. WU Xiaohui (吳曉輝先生) (*Chairman*)  
Mr. YUAN Jun (袁駿先生)  
Mr. LIU Senlin (劉森林先生)

### REMUNERATION COMMITTEE

Mr. YUAN Jun (袁駿先生) (*Chairman*)  
Mr. LUO Yi (羅毅先生)  
Mr. CHEN Zhaoyang (陳朝陽先生)

### NOMINATION COMMITTEE

Dr. XU Ke (徐克博士) (*Chairman*)  
Mr. WU Xiaohui (吳曉輝先生)  
Mr. LUO Yi (羅毅先生)

### AUDITOR

PricewaterhouseCoopers  
*Certified Public Accountants*  
Registered Public Interest Entity Auditor  
22/F, Prince's Building  
Central  
Hong Kong

### REGISTERED OFFICE

Room 1002, 10th Floor, 10# Building  
Public R&D Centre  
Xinqi Zhoudong Avenue South  
Chinese Medicine Science and Technology  
Innovation City  
Ganjiang New District  
Jiangxi province, China

### HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN CHINA

Building 2, 2 Minzuyuan  
Minzuyuan Road  
Chaoyang District  
Beijing, China



## Corporate Information

### PRINCIPAL PLACE OF BUSINESS IN HONG KONG

40/F, Dah Sing Financial Centre  
No. 248 Queen's Road East  
Wanchai  
Hong Kong

### PRINCIPAL BANK

China Construction Bank Corporation,  
Nanchang Branch  
No. 288 Hongdu North Avenue  
Donghu District  
Nanchang  
Jiangxi province, China

### COMPLIANCE ADVISER

Red Sun Capital Limited  
Room 310, 3/F  
China Insurance Group Building  
141 Des Voeux Road Central  
Hong Kong

### HONG KONG LEGAL ADVISER

Sullivan & Cromwell (Hong Kong) LLP  
20th Floor, Alexandra House  
18 Chater Road  
Central  
Hong Kong, China

### H SHARE REGISTRAR

Tricor Investor Services Limited  
17/F, Far East Finance Centre  
16 Harcourt Road  
Hong Kong

### STOCK CODE

H Share: 02522

### COMPANY WEBSITE

[www.rimag.com.cn](http://www.rimag.com.cn)



## Financial and Business Highlights

### FINANCIAL HIGHLIGHTS

	Six months ended June 30,		
	2024 (Unaudited) RMB'000	2023 (Unaudited) RMB'000	Year-on- year change
Revenue	413,713	529,779	-21.9%
Gross profit	159,659	188,631	-15.4%
Profit for the period	962	47,292	-98.0%
Profit for the period attributable to owners of the company	3,836	42,979	-91.1%
<b>Non-IFRS Measures*:</b>			
EBITDA	114,132	155,321	-26.5%
Adjusted EBITDA	149,058	167,309	-10.9%
Adjusted net profit	35,888	59,280	-39.5%

\* For more details, please see “Management Discussion and Analysis – Financial Review – Non-IFRS Measures”.

The year-on-year decline in the Group’s interim results during the Reporting Period was mainly due to the slowdown in demand of service procurement from various medical institutions as well as the bidding process under the impact of the macro-economic slowdown and the tight regulatory environment of the healthcare industry. Nevertheless, the Group’s revenue from its core imaging center services remained relatively stable, and still maintained solid business fundamentals and continued to expand the development of new projects even in the face of the impact of the macroeconomic slowdown and the tight regulatory environment in the healthcare industry. Meanwhile, comparing to the second half of 2023, the Group’s interim results during the Reporting Period still maintained a stable period-to-period growth. We believe that the whole healthcare industry’s overall demand for imaging services is still in a relatively stable condition, especially in the context of the country’s proposal to develop the “Thousand Counties Project (千縣工程)” and to carry out the development of disciplines and the enhancement of the primary level, as well as to encourage the equipment update of primary medical institutions. Rimag’s imaging center services and imaging solution services can both be the solution for primary medical institutions to complete the improvement of equipment and facilities as well as to solidly enhance their imaging service capabilities.

### BUSINESS HIGHLIGHTS

As a leading medical group specialized in medical imaging in China, we are the only operator and manager of a medical imaging platform that provides diversified imaging services and value to the entire medical imaging industry chain in China. Since the beginning of 2024, we have made the following progress in our business:

- **Listing on the Stock Exchange.** On June 7, 2024, the H Shares of the Company were successfully listed on the Main Board of the Stock Exchange, making us the “first listed medical imaging services company in China (中國醫學影像服務第一股)”. The net proceeds from the Global Offering amounted to approximately HK\$183.48 million.
- **Continued expansion of medical imaging center network.** During the Reporting Period, we newly developed 12 imaging center projects and newly put 9 imaging center projects into operation. As at June 30, 2024, our medical imaging center network covered 17 provinces, autonomous regions and municipalities in the PRC, with an aggregate of 105 imaging centers in operation, achieving the continued expansion and layout of medical imaging center network and reinforcing our leading position in the industry.
- **Technology and industry achievements.** During the Reporting Period, from the perspective of the Group’s own strategic development and industry needs, we organized clinical experts and medical imaging experts to undertake the development of a series of standards for medical imaging examinations, and established the “Standard for the Naming and Coding of Medical Imaging Examination Items 《醫學影像檢查項目名稱及編碼標準》” (the “Standard”) to provide the basis for the standardization and unification of the Group’s medical imaging data and to lay the foundation for the Group to achieve high quality development and value for data service. The Standard was reviewed by a team of national expert reviewers organized by the PMPH Research Institute (人衛研究院) and was formally released on January 1, 2024 and formally implemented on March 1, 2024.

# Management Discussion and Analysis

## I. BUSINESS REVIEW

### Overview

As a leading medical group specialized in medical imaging in China, we are the only operator and manager of a medical imaging platform that provides diversified imaging services and value to the entire medical imaging industry chain in China. On June 7, 2024, the H Shares of the Company were successfully listed on the Main Board of the Stock Exchange, making us the “first listed medical imaging services company in China (中國醫學影像服務第一股)”. The net proceeds from the Global Offering amounted to approximately HK\$183.48 million.

We are always committed to center around medical imaging services, with the support of technology innovation and model innovation (such as the model of our regional collaborative imaging centers), and build up the strategic layout of “expanding and building centers (開疆拓土建中心)”, “deep plowing and cultivating operation (深耕細作抓運營)”, “seeking improvement in data services (數據服務謀跨越)” and “building a platform for ecological empowerment (生態賦能搭平台)”, aiming to establish a medical imaging platform with leading industry chain integration and eco-organization capabilities in China. We always adhere to positioning medical imaging services as the core of our business, building up our service capability output through our three key business segments, namely imaging center services, imaging solution services and Rimag Cloud services. Apart from standard medical imaging service options, we can also provide customized and menu-based imaging service packages to satisfy different pain points and needs of our customers, while we always maintain consistent underlying service strengths and ecosystem.

In July 2024, the Third Plenary Session of the National People’s Congress further proposed in the “Decision of the Chinese Central Government on Further Comprehensively Deepening Reform and Advancing Chinese-Style Modernization 《中國中央關於進一步全面深化改革推進中國式現代化的決定》” to deepen the reform of the medical and healthcare system, promote the expansion and downward penetration and balanced regional layout of high-quality medical resources, accelerate the construction of a hierarchical diagnostic and treatment system, promote the construction of close-knit medical consortiums, and strengthen the medical and healthcare services for grassroots level. Such proposal further strengthened the Company’s correct path of developing its business by “deeply rooting in city and county-level administrative regions with relatively weak bases of hospital imaging, uneven development and high market shares”.

During the Reporting Period, we generated revenue of approximately RMB413.7 million, primarily from: (i) imaging center services; (ii) imaging solution services; and (iii) Rimag Cloud services.

## Management Discussion and Analysis

### Imaging Center Services

Our imaging center services aim to solve the pain points of medical imaging industry, achieve the empowerment and balanced distribution of quality medical imaging resources, and form a network of chain medical imaging centers. Our imaging center services include: (i) imaging examination and diagnostic services offered at our own imaging centers, among other things; and (ii) operational management services offered to imaging centers of our business partners. We provide the foregoing services through four types of imaging centers, namely: (i) flagship imaging centers; (ii) regional collaborative imaging centers; (iii) specialized medical consortium imaging centers; and (iv) operational management imaging centers.

During the Reporting Period, our revenue generated from the imaging center services was approximately RMB319.0 million, representing (i) a year-on-year decrease of 5.9% as compared to approximately RMB339.0 million for the six months ended June 30, 2023; and (ii) a period-to-period increase of RMB19.9 million or 6.7% against the trend, as compared to approximately RMB299.0 million for the second half of 2023.

On the whole, our revenue from the core imaging center services remained relatively stable, and still maintained solid business fundamentals and continued to expand the development of new projects even in the face of the impact of the macroeconomic slowdown and the tight regulatory environment in the healthcare industry.

During the Reporting Period, we continued to expand and develop our imaging center services in China and reinforced our leading market position as follows:

- A. **Developed projects.** During the six months ended June 30, 2024, we newly developed 12 imaging centers (based on the signing of agreements), comprising 1 regional collaborative imaging center, 9 specialized medical consortium imaging centers and 2 operational management imaging centers. As at June 30, 2024, our Company had developed a total number of 119 imaging centers, comprising 9 flagship imaging centers, 28 regional collaborative imaging centers, 66 specialized medical consortium imaging centers and 16 operational management imaging centers.



## Management Discussion and Analysis

- B. **Operated projects.** During the six months ended June 30, 2024, we commenced the operation of 9 imaging centers (based on the signing of operation confirmation letters), comprising 1 regional collaborative imaging center, 4 specialized medical consortium imaging centers and 4 operational management imaging centers. As at June 30, 2024, our Company operated a total number of 105 imaging centers, comprising 9 flagship imaging centers, 25 regional collaborative imaging centers, 54 specialized medical consortium imaging centers and 17 operational management imaging centers, with a total of 32 third-party medical imaging center licenses in effect in China.
- C. **Construction-in-progress projects.** As at June 30, 2024, there were 14 construction-in-progress imaging centers (which refer to the imaging centers under development but not yet put into operation), comprising 3 regional collaborative imaging centers and 11 specialized medical consortium imaging centers, which are expected to commence operation in the second half of 2024.

Under the premise of having a nation-wide layout of business network, we always target to align the enhancement of our professional medical imaging service capabilities with the expansion of our business operations. During the Reporting Period, we made the following improvements in our professional medical imaging service capabilities:

- A. The Group continuously held internal professional training courses for medical imaging specialties. The Group conducted 78 regular training courses under the imaging category, including 35 radiology training courses, 11 ultrasound training courses, 12 nuclear medicine training courses and 20 nursing training courses. Each imaging center strengthened its professional capabilities from its own perspective. In addition to regular courses with pre-determined subjects, the Group's Imaging Academy also coordinated interest courses in three dimensions: conducting 14 sub-specialty discipline training sessions by inviting top experts in the industry to give lectures to help physicians, technicians and nursing staff broaden their professional knowledge and improve their professional level, covering 1,134 person-times in a total of 74 sessions; conducting 86 imaging technology application training sessions by providing one-on-one instructional training on the use of imaging technology, to accurately improve the professional skills of frontline medical technicians; conducting 7 phases of medical imaging leadership training to cultivate leaders in medical imaging center management through management-oriented training and create all-round department directors with professionalism management.

## Management Discussion and Analysis

- B. Disease-specific imaging examinations and imaging specialties technology with the brand mark of Rimag continued to develop and create high net value income for the Group, forming a unique and innovative path for the Group's professional operation and development. Through preliminary attempts, the Group launched disease-specific imaging examinations for scoliosis, cardiovascular and cerebrovascular diseases, Alzheimer's disease, rectal cancer staging, and arterial plaque screening (vascular high-resolution) in the first phase, and successfully joined the "China AD Preclinical Alliance (中國AD臨床前期聯盟)", realizing the linkage resource circulation between authoritative medical organizations and the Group's imaging centers in the clinical research on aging diseases in China; launched multiple imaging specialty technologies, such as MR examination of temporomandibular joints, MR scanning of breast + dynamic enhancement scanning, ultrasound of muscles and bones, MR scanning of cranial nerves, and CT examination of stomach and small intestines.
- C. Continued to maintain the academic communication between radiologists and clinicians. Our imaging centers continued to communicate with clinicians to deliver new technologies and examinations, and organized a total of 375 clinical academic conferences. Through the communication and knowledge transfer between imaging centers and clinicians, based on high-quality imaging, we helped clinicians set up specialty clinics (such as brain health specialty clinics, lung nodule specialty clinics, carotid plaque specialty clinics, etc.) to develop key clinical specialties and enhance the overall diagnostic and treatment technology and academic development of hospitals.
- D. Emphasized the cultivation and reserve of the Group's professional talents. We always value the cultivation of new force and the reserve of professional talents. The Group's Imaging Academy focused on promoting cooperation with medical colleges and universities in respect of apprenticeship, internship and directed training and employment, the establishment of training bases, and the research and development cooperation with college expert teams in the area of artificial intelligence, and achieved multi-dimensional cooperation with 5 institutions.

## Management Discussion and Analysis

### Imaging Solution Services

Our imaging solution services primarily include: (i) equipment selection and configuration; (ii) infrastructure renovation services; (iii) training services; (iv) repair and maintenance services; and (v) Rimag Cloud platform-related services. We generally offer our service modules, primarily including: equipment selection and configuration services, infrastructure renovation services, and training services, as equipment-centered one-stop solution packages to our customers. Customers are also able to purchase separate service modules, such as repair and maintenance services, from us. Our goal is to enhance our customers' ability to serve patients through our imaging empowering solutions, realizing that "using a good equipment is more important than buying a good equipment".

During the Reporting Period, our revenue generated from the imaging solution services was approximately RMB85.2 million, representing (i) a year-on-year decrease of 54.3% as compared to approximately RMB186.5 million for the six months ended June 30, 2023; and (ii) a period-to-period decrease of RMB6.7 million or 7.3%, as compared to approximately RMB91.9 million for the second half of 2023.

The decline in revenue from imaging solution services was mainly because the tight regulatory environment in the healthcare industry resulted in the slowdown of the various procurement demand from medical institutions across the industry, as well as the slowdown of the bidding process of projects with demand, which caused the progress of projects not yet reach the stage of revenue recognition. Notwithstanding the above impact of the external policy environment, we believe that the overall demand for imaging solution services in the industry as a whole is still in a relatively stable condition.

### Rimag Cloud Services

Our Rimag Cloud platform is designed with reference to the whole process and features step-by-step R&D in a modular manner. Our Rimag Cloud services help medical institutions reduce labor costs, standardize workflow procedures, and realize data-driven management, thereby improving the service capabilities of these medical institutions and the medical experience of their patients. Our Rimag Cloud platform is composed of various modules. The modules of our commercialized Rimag Cloud platform mainly include: (i) medical imaging workflow modules; and (ii) operational management modules.

## Management Discussion and Analysis

As of June 30, 2024, we had 91 software copyright certificates and 2 medical device registration certificates relating to the Rimag Cloud platform, and applied for 4 invention patents under review.

Our revenue generated from the Rimag Cloud services for the six months ended June 30, 2024 was approximately RMB9.6 million, representing an increase of 123.3% as compared to approximately RMB4.3 million for the six months ended June 30, 2023. The increase was primarily because we tapped into the informatization needs of hospital partners and brought in secondary sales. During the Reporting Period, our revenue generated from Rimag Cloud services increased by RMB1.4 million, as compared to RMB8.2 million for the second half of 2023, representing a period-to-period increase of 17.1%.


### **Integrated One-Stop Ecosystem Platform Centered Around Our Three Key Business Segments**

We build our service capability output through three parts of our business, namely imaging center services, imaging solution services and Rimag Cloud services, the three of which are mutually supportive and transformative. Targeting different pain points and needs of our customers, we can provide different service packages to satisfy their needs. These three core businesses form a one-stop ecosystem platform, making it link the different players, and we enable each role in this ecosystem platform to gain their own value embodiment or value interaction.

## Management Discussion and Analysis

The following diagram illustrates the integrated one-stop ecosystem platform centered around our three key business segments:

**Three core businesses of the Company form a one-stop ecosystem connecting different participants**



## II. FINANCIAL REVIEW

### Overview

The following discussion is based on, and should be read in conjunction with, the financial information and the notes included elsewhere in this interim report.

During the Reporting Period, the overall business of the Group achieved stable development, with recorded revenue of approximately RMB413.7 million, adjusted net profit of approximately RMB35.9 million.



## Management Discussion and Analysis

### Revenue

During the Reporting Period, we generated revenue primarily from three business lines, namely: (i) imaging center services; (ii) imaging solution services and (iii) Rimag Cloud services. The following table sets forth the components of our revenue for the periods indicated:

		Six months ended 30 June	
		2024	2023
		RMB'000	RMB'000
Imaging center services	Satisfaction of performance obligation		
– Flagship imaging centers	Point in time	60,424	73,607
– Regional collaborative imaging centers	Point in time	182,677	184,654
– Specialized medical consortium imaging centers	Overtime	53,995	59,191
– Operational management imaging centers	Overtime	21,857	21,573
		318,953	339,025
Imaging solution services			
– Imaging equipment solutions	Point in time	84,552	186,464
– Equipment maintenance services	Overtime	628	–
		85,180	186,464
Rimag Cloud services			
– Cloud platform services	Overtime	5,580	4,290
– Sales of software	Point in time	4,000	–
		9,580	4,290
		413,713	529,779

During the Reporting Period, the Group's revenue was approximately RMB413.7 million, representing (i) a year-on-year decrease of 21.9% as compared to approximately RMB529.8 million for the six months ended June 30, 2023; and (ii) a period-to-period increase of RMB14.6 million or 3.7% against the trend, as compared to the second half of 2023.



## Management Discussion and Analysis

The decline in the Group's overall revenue was mainly due to the slowdown of procurement demand from medical institutions which resulted in the decline in revenue from imaging solution services. However, the revenue from the Group's core imaging center services remained relatively stable, and we maintained solid business fundamentals and continued to expand the development of new projects, even in the face of the impact of macro-economic slowdown and the tight regulatory environment of the healthcare industry. We believe that the overall demand for imaging services in the industry as a whole remains relatively stable, especially in the context of the country's proposal to develop the "Thousand Counties Project (千縣工程)" and to update the equipment of primary medical institutions, as well as to encourage the equipment update of primary medical institutions. Services like imaging center services and imaging solution services can be good solution for primary medical institutions to complete the target of improving equipment and facilities as well as the needs to solidly enhance their imaging service capabilities.

### Cost of Sales

During the Reporting Period, our cost of sales primarily consisted of trading medical equipment, employee benefit expenses and depreciation of property, plant and equipment. The Group's cost of sales for the six months ended June 30, 2024 was approximately RMB254.1 million, representing a decrease of 25.5% as compared to approximately RMB341.1 million for the six months ended June 30, 2023. The decrease was primarily attributable to the drop in the trading medical equipment due to the decreased volume of sales orders of imaging solution services.

### Gross Profit and Gross Margin

Gross profit represents our revenue less our cost of sales. As a result of the aforementioned factors, the gross profit of the Group decreased by 15.3% from approximately RMB188.6 million for the six months ended June 30, 2023 to approximately RMB159.7 million for the six months ended June 30, 2024. The decrease was primarily caused by the drop in the volume of examinations conducted by our imaging centers resulted from the slowdown of macro-economy and changes in market environment. Comparing to the second half of 2023, our gross profit increased by RMB15.7 million during the Reporting Period, due to the period-to-period increase of revenue from imaging center services.

## Management Discussion and Analysis

Gross margin represents our gross profit as a percentage of our revenue. The gross margin of the Group increased from 35.6% for the six months ended June 30, 2023 to 36.1% for the second half of 2023, and further increased to 38.6% for the six months ended June 30, 2024. The increase was mainly attributable to the increased revenue contribution of imaging center services as well as the continued enhancement in cost control to improve the overall economic efficiency.

### Selling Expenses

During the Reporting Period, our selling expenses primarily consisted of employee benefit expenses and marketing fees. The Group's selling expenses for the six months ended June 30, 2024 was approximately RMB33.0 million, representing a decrease of 4.3% as compared to approximately RMB34.5 million for the six months ended June 30, 2023. The decrease was mainly due to the reduced offline marketing activities resulting in decreased marketing fees.

### Administrative Expenses

During the Reporting Period, our administrative expenses primarily consisted of employee benefit expenses, listing expenses, depreciation of right-of-use assets, traveling expenses, office expenses and entertainment fees. The Group's administrative expenses for the six months ended June 30, 2024 was approximately RMB111.1 million, representing an increase of 37.0% as compared to approximately RMB81.1 million for the six months ended June 30, 2023. The increase was primarily attributable to the increased listing expenses as the Global Offering proceeded to the mid-to-late stage during the Reporting Period.

### Research and Development Expenses

During the Reporting Period, our research and development expenses primarily consisted of employee benefit expenses, depreciation and amortization, and traveling expenses. The Group's R&D expenses for the six months ended June 30, 2024 was approximately RMB5.7 million, representing a decrease of 3.4% as compared to approximately RMB5.9 million for the six months ended June 30, 2023. The decrease was mainly attributable to the cost control of R&D personnel's travelling expenses.

## Management Discussion and Analysis

### Finance Income and Costs

During the Reporting Period, our finance income represents interest income on bank deposits. Finance costs primarily consisted of (i) interest expenses on bank borrowings; (ii) finance expenses on lease liabilities; and (iii) interest expenses on other borrowings. The following table sets forth a breakdown of our finance income and costs for the periods indicated:

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
Finance income:		
– Interest income from bank deposits	1,143	1,970
Finance costs:		
– Interest expenses on bank borrowings	(2,381)	(2,659)
– Interest expenses on other borrowings	(4,572)	(6,298)
– Finance expenses on lease liabilities	(4,116)	(3,997)
	(11,069)	(12,954)
Amount capitalized	20	326
Total finance costs	(11,049)	(12,628)
Finance costs – net	(9,906)	(10,658)

Our net finance costs for the six months ended June 30, 2024 were approximately RMB9.9 million, representing a decrease of 7.5% as compared to approximately RMB10.7 million for the six months ended June 30, 2023. The decrease in net finance costs was primarily attributable to the decrease in the weighted average balance of bank borrowings and finance leases.

### Income Tax Expense

During the Reporting Period, our income tax expense was RMB3.4 million. Our income tax expense in respect of our operations in the PRC was subject to the statutory tax rate of 25% or preferential tax rate on the assessable profits for the six months ended June 30, 2024, based on the existing legislation, interpretations and practices in respect thereof.

## Management Discussion and Analysis

### Profit for the period

As a result of the foregoing, our profit for the period decreased by 97.9% from approximately RMB47.3 million for the six months ended June 30, 2023 to approximately RMB1.0 million for the six months ended June 30, 2024. The decrease was mainly because (i) the slowdown of macro-economy and change in market conditions caused adverse impact and (ii) our H Shares were successfully listed on the Main Board of the Stock Exchange on June 7, 2024, resulting in listing related expenses.

Comparing to the second half of 2023, our profit for the period increased by RMB11.7 million during the Reporting Period, representing a period-to-period increase of 109%, which maintained the trend of continuously improving overall profitability.

### Non-IFRS Measures

	For the six months ended June 30,		
	2024 (Unaudited) RMB'000	2023 (Unaudited) RMB'000	Year-on- year change
<b>Non-IFRS Measures:</b>			
EBITDA	114,132	155,321	-26.5%
Adjusted EBITDA	149,058	167,309	-10.9%
Adjusted net profit	35,888	59,280	-39.5%

To supplement our consolidated statement of profit which are presented in accordance with IFRS, we also use EBITDA (non-IFRS measure), adjusted EBITDA (non-IFRS measure) and adjusted net profit (non-IFRS measure), which are not required by, or presented in accordance with, IFRS.

We believe that these measures provide useful information to investors and others in understanding and evaluating our condensed consolidated interim income statement in the same manner as they help our management. However, our presentation of EBITDA (non-IFRS measure), adjusted EBITDA (non-IFRS measure) and adjusted net profit (non-IFRS measure) may not be comparable to similarly titled measures presented by other companies. The use of these non-IFRS measures has limitations as an analytical tool and, as such, they should not be considered in isolation from, or as substitute for analysis of, our consolidated statements of comprehensive income or financial condition as reported under IFRS. In addition, the non-IFRS measures may be defined differently from similar terms used by other companies.



## Management Discussion and Analysis

There are two components to the adjusted EBITDA (non-IFRS measure) metric: (1) EBITDA (non-IFRS measure), which we define as profit before income tax plus finance costs, depreciation of property, plant and equipment, depreciation of right-of-use assets and amortization of intangible assets, less finance income; and (2) adjustments to EBITDA (non-IFRS measure), which include items of share-based payments expenses and listing expenses. These reconciling items are non-cash items and do not result in cash outflow. We exclude listing expenses, as they arose from activities relating to the Global Offering.

The following table reconciles our EBITDA (non-IFRS measure) and adjusted EBITDA (non-IFRS measure) in accordance with IFRS, our profit before income tax, for the periods indicated:

	<b>For the six months ended June 30,</b>	
	<b>2024 (Unaudited) RMB'000</b>	<b>2023 (Unaudited) RMB'000</b>
<b>Profit before income tax</b>	4,374	55,147
Add: Finance costs	11,049	12,628
Add: Depreciation of property, plant and equipment	79,424	73,543
Add: Depreciation of right-of-use assets	18,496	14,853
Add: Amortization of intangible assets	1,932	1,120
Less: Finance income	(1,143)	(1,970)
<b>EBITDA (non-IFRS measure)</b>	<b>114,132</b>	<b>155,321</b>
Add: Share-based payments expenses	472	1,501
Add: Listing expenses	34,454	10,487
<b>Adjusted EBITDA (non-IFRS measure)</b>	<b>149,058</b>	<b>167,309</b>

## Management Discussion and Analysis

We define adjusted net profit (non-IFRS measure) as profit for the period adjusted for items of share-based payments expenses and listing expenses. We adjusted these items for the same reasons as stated in the discussion of adjustments to EBITDA (non-IFRS measure) above. The following table reconciles our adjusted net profit (non-IFRS measure) in accordance with IFRS, our profit for the period, for the periods indicated:

	For the six months ended June 30,	
	2024 (Unaudited) RMB'000	2023 (Unaudited) RMB'000
<b>Profit for the period</b>	962	47,292
Add: Share-based payments expenses	472	1,501
Add: Listing expenses	34,454	10,487
<b>Adjusted net profit (non-IFRS measure)</b>	<b>35,888</b>	<b>59,280</b>

Our adjusted net profit for the Reporting Period reached approximately RMB35.9 million, representing a year-on-year decrease of 39.5% as compared to approximately RMB59.3 million for the six months ended June 30, 2023.

In terms of the Group's adjusted EBITDA and adjusted net profit, there was certain decline during the Reporting Period as compared to the six months ended June 30, 2023. Such decline was mainly due to the year-on-year decrease in the overall revenue (especially the decrease in the revenue from the imaging solution services). However, there was significant period-to-period increase as compared to the second half of 2023, which reflected that the Group as a whole is still in a trend of stable improvement in respect of its profitability.

### Capital Management

We monitors capital (including shares and borrowings) by regularly reviewing the capital structure. Our objectives when managing capital are to safeguard our ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the costs of capital.

## Management Discussion and Analysis

### Liquidity and Capital Resources

During the Reporting Period, we funded our working capital primarily from net cash generated from operating activities, bank borrowings, finance leases and equity financing. Our net cash generated from operating activities mainly consists of profit before income tax adjusted for (i) non-cash items, such as net finance costs, depreciation of property, plant and equipment and depreciation of right-of-use assets; (ii) the effects of changes in working capital, such as contract liabilities, trade payables, other payables and accruals, trade receivables and other receivables and prepayments; and (iii) the effects of interest received and income tax paid.

We had cash and cash equivalents of approximately RMB188.8 and RMB305.5 million as at December 31, 2023 and June 30, 2024, respectively. The increase in our cash and cash equivalents primarily reflected the proceeds from the Global Offering received during the Reporting Period.

We recorded net cash generated from operating activities of approximately RMB97.4 million and RMB34.1 million for the six months ended June 30, 2023 and 2024, respectively. The decrease was primarily due to the reduced recovery of receivables from imaging center services and imaging solution services.

### Borrowings and Gearing Ratio

As at June 30, 2024, the aggregate balance of our borrowings was approximately RMB265.4 million (approximately RMB210.0 million as at December 31, 2023), which were all made in RMB, and approximately RMB161.9 million of them were at fixed interest rates. As at June 30, 2024, all of our borrowings had been fully drawdown, and there was no unutilized loan facilities from banks or financial leasing companies.

The gearing ratio (calculated based on total borrowings divided by total equity and multiplied by 100%) of the Group as at June 30, 2024 was 17.0%, representing an increase of 1.3% as compared to 15.7% as at December 31, 2023. The increase was primarily attributable to the increased finance lease and bank borrowings corresponding to the newly developed imaging center projects.

### Net Current Assets

Our net current assets, as at June 30, 2024 were approximately RMB448.1 million, representing an increase of 47.3% as compared to approximately RMB304.3 million as at December 31, 2023. The increase was primarily attributable to proceeds raised from the Global Offering and the increase in trade receivables.

## Management Discussion and Analysis

### Currency Risk

We are engaged in the provision of medical imaging services through the establishment of medical imaging network, as well as operational management services, imaging solution services and Rimag Cloud services in the PRC with almost all the transactions denominated and settled in RMB, which is the functional currency of the group companies. Therefore, our foreign exchange risk is limited. We currently do not have a foreign currency hedging policy, and manages its foreign currency risk by closely monitoring the movement of the foreign currency rates. As at June 30, 2024, we had no material foreign currency denominated assets and liabilities. Therefore, we did not have any significant foreign exchange risk.

### Significant Investments, Material Acquisitions and Disposals/Future Plans in relation to Significant Investments or Capital Assets

As at June 30, 2024, we did not have any significant investments, material acquisitions and disposals or any future plans in relation to significant investments or capital assets. Each of the investments held by us as a percentage of the Group's total assets as at June 30, 2024 did not amount to 5% or more.

### Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures

Since the Listing Date and up to June 30, 2024, we did not have material acquisitions or disposals of subsidiaries, associates and joint ventures.

### Capital Expenditure

During the Reporting Period, our total capital expenditure amounted to approximately RMB180.3 million, which was incurred mainly for the purchase of equipment and intangible assets such as software.

### Pledge of Assets

As at June 30, 2024, we had pledged machineries, cash at banks, trade receivable and equity of our subsidiaries in aggregate of approximately RMB607.6 million.

### Contingent Liabilities

As at June 30, 2024, we did not have any material contingent liabilities, guarantee, legal, arbitration or administrative proceedings that were expected to materially and adversely affect our financial condition or results of operations.

## Management Discussion and Analysis

### Employees and Remuneration Policies

As at June 30, 2024, we had 1,667 employees and medical professionals. During the Reporting Period, our employee benefit expenses amounted to approximately RMB100.5 million (six months ended June 30, 2023: approximately RMB93.4 million).

We are committed to establishing competitive and fair remuneration. In order to effectively motivate our employees, we continually refine our remuneration and incentive policies through market research. We conduct performance evaluation of our employees semiannually to provide feedback on their performance. Compensation for our employees typically consists of basic salary and a performance-based bonus. We provide social insurance plans and housing provident funds in accordance with applicable PRC laws and regulations to our employees. We pay great attention to our employees' welfare, and continually improve our welfare system. We offer employees additional benefits such as annual leave, stipend, supplementary medical insurance, annuity, health examinations and medical insurance for family members, among other things.

### III. FUTURE DEVELOPMENT AND STRATEGIES

Our goal is to become the foremost medical group with a focus on imaging in China and worldwide. We aim to establish a dominant medical imaging solution service platform that can efficiently integrate resources across the industry value chain and promote a thriving entrepreneurial business network. To achieve this, we plan to implement the following strategies:

#### 1. Further expand our medical imaging center network and enrich the offerings of our imaging solution services to strengthen our industry-leading position

We actively develop regional collaborative imaging centers, and intend to strategically prioritize our resource integration and investments in regions with relatively uneven distribution of medical resources. In particular, we choose to establish or acquire regional collaborative imaging centers in regions where we have existing support from government policies and business partners and the potential of which has not yet been fully exploited. At the same time, we can adopt various investment and cooperation strategies during the investment process, such as joint venture with local state-owned platforms to build regional collaborative imaging centers and provide medical imaging examination and diagnostic services and image operation and management services in the region, so as to realize the sharing of medical imaging equipment, sharing of medical imaging doctors, and exchange of medical imaging data in the region, which is conducive to the realization of the improvement of the level of the local medical imaging diagnostic capacities without any governmental investment and the benefit of the people.



## Management Discussion and Analysis

We are actively implementing the national development policy of hierarchical diagnosis and treatment and strengthening the primary level. We plan to further develop specialized medical consortium imaging centers and operational management imaging centers to realize the extension and penetration of our imaging service capabilities. The approach is for us to further develop specialized medical consortium imaging centers and operational management imaging centers in the regions where we have already invested in imaging centers, so as to further extend and expand our medical imaging service capabilities in these regions and to increase market penetration and achieve market expansion.

Meanwhile, based on our existing layout of the flagship imaging centers, we plan to establish or acquire more flagship imaging centers in high-tier cities with large populations, high levels of consumer spending, and highly differentiated demands.

We also aim to provide diversified medical imaging services, and strategically select regions with great potential for development. We intend to provide imaging solution services and Rimag Cloud services to potential customers to realize the rapid expansion of our business. In addition, we plan to grasp market opportunities with such customers and convert them to business partners of operational management imaging centers and regional collaborative imaging centers.

Additionally, in the long run, we plan to enter overseas markets and establish or acquire imaging centers in certain countries that are undervalued and have medical needs and favorable policies.

### **2. Enhance our operation and management strength, and continuously improve our professional level and branding capacities**

We target to continuously enhance our operation and management strength through the improvement of professionalism, mechanism, and management capability, to achieve the enhancement of “imaging services capacity” in the whole imaging process of “radiologists, radiologic technologists, managers and clinicians”.

We will focus on specialized diseases, utilize the role of medical imaging in the field of disease targeting, and use imaging as a link to help public hospitals which have purchased our medical imaging services build and create specialized outpatient clinics and explore unique technologies, so as to better serve the needs of patients at the local level, such as cardiovascular and cerebrovascular specialty clinics and epilepsy specialty clinics.

## Management Discussion and Analysis

We will promote imaging-enabled disease prevention, utilize the value of medical imaging in health management and early screening prevention, such as utilizing the value of imaging in the “prevention of sudden death, early screening of tumors, Alzheimer’s disease, cardiovascular health and etc.”, which is conducive to the improvement of national health and good quality of life. Through the Company’s investment in the incubation of Hanji Health Management (Shanghai) Co., Ltd. (漢吉健康管理(上海)有限公司), a company focusing on health management and physical examination, we will achieve the value input to the health check field of public hospitals, and realize a win-win development.

We will promote the operational mentorship system. The mentorship system can deeply implement the Group’s operational philosophy, promote the transmission of operational concepts and experience to new imaging centers, and ensure that new imaging centers can quickly learn and apply the Group’s best operational practices, thereby generally enhancing the operation and management capabilities within our system.

We will further optimize operation SOPs, formulate and improve different SOP requirements according to different business types and natures, match the reasonable allocation of approval personnel, and improve the accuracy of approval at various nodes; optimize the system operation page, improve the user’s operational convenience, and make it convenient for managers to check the status of the project.

### **3. Continually invest in R&D to reinforce our Rimag Cloud service capabilities and further support the rapid and effective business expansion of our medical imaging centers and imaging solution services**

As an essential tool that supports our operation and management of imaging centers and imaging solution services, the Rimag Cloud platform is also expected to be one of our future revenue growth drivers. We intend to continually invest in R&D, either through strengthening our in-house capabilities or cooperation with third parties. We expect to recruit personnel with rich experience in fields such as data analytics and information systems so as to develop platform products for the key participants in the medical imaging services industry, enrich our current cloud-based product portfolio, and continuously expand our service capabilities and offerings. In particular, we intend to increase our investment in the following aspects:

## Management Discussion and Analysis

We will actively explore the value of data services and data assets, focus on data asset management, and do a good job in the construction of data application platforms such as standardization of inspection items, image master data management, and refined quality control. We plan to continuously enhance our capabilities in data standardization. We intend to keep standardizing our existing medical imaging data to increase their value. Through data accumulation, we expect to form our data-driven competitiveness, for purposes of laying the foundation for subsequent workflow standardization, big data analysis and application, and cooperation with medical imaging AI service providers;

We will enhance the R&D capability around the application of the whole process of imaging services to ensure the efficient operation and empowerment of the imaging center. We plan to continually invest in management systems facilitating the operation of imaging centers, such as smart SOP systems, refined operational management systems, and whole process quality control systems;

We intend to continually invest in application platforms such as health management service platforms and remote consultation platforms that serve to enhance customer experience, broaden service settings, and diversify profit scenarios and models by leveraging leading technology advancements such as those in AI and deep learning; and

We plan to collaborate with third parties to formulate knowledge pool and knowledge graphs relating to medical imaging and clinical diseases. Moreover, through the continual development of our AI tools based on natural language processing and knowledge graphs, we plan to extend the application of AI technology to patient consultation, diagnostic imaging, quality control, business data analysis and other processes. For example, we intend to utilize AI technology to provide patients with smart consultation, medical guidance and report interpretation services.

We believe that the above-mentioned investments in R&D will help to strengthen our capabilities in operating and managing imaging centers and providing imaging solution services. This can further enhance our overall profitability, expand our business, and increase our brand influence.



## Management Discussion and Analysis

### 4. **Strengthen Rimag Imaging Academy, build an effective long-term talent cultivation system, and continue to nurture and attract skilled medical imaging and managerial talents**

We expect to continually reinforce talent cultivation at our Rimag Imaging Academy and set up and maintain a talent cultivation system. By providing training and recruiting talented individuals, we aim to strengthen our team's capabilities to support our expanding business. We plan to continuously focus on the following aspects:

We plan to continue investing in and upgrading our existing Radiology Management Business Administration (RMBA) training system, cultivating more versatile professionals with both medical background and business managerial skills. We believe that these trained imaging center management personnel will become the cornerstone of our business development;

We expect to create a talent development path that integrates operations and market development, selecting individuals with experience in operating imaging centers to engage in market development work. We believe that this approach will be more conducive to the development of value-based investments; and

We intend to continue collaborating with universities to jointly build medical imaging bootcamps, and set up specialized talent cultivation programs, thereby providing a long-term and stable talent pool for our business development.

By continual nurturing of various types of talents, setting up clear promotion career paths and competitive incentive mechanisms to clarify their career development path and motivate them, and strengthening employees' sense of belonging, we aim to provide strong support to the rapid expansion of imaging centers, professional quality assurance, and improvement in operational capabilities and operational performance.

## Management Discussion and Analysis

### 5. Enhance strategic cooperation with industry upstream and downstream stakeholders to continuously enhance our capabilities to integrate the medical imaging industry and coordinate an business network

We plan to intensify our strategic partnerships with upstream and downstream companies, including equipment providers, equipment maintenance companies, medical imaging AI service providers, and industry associations, so as to enhance our capabilities to coordinate a business network and integrate resources along the industry value chain. This is expected to further help us improve operational capabilities and efficiency, and solidify our industry position.

**Equipment providers.** We plan to deepen our collaboration with equipment providers to utilize our experience and knowledge in equipment usage, convert it into our intellectual property, and cooperate with manufacturers to produce customized equipment.

**Equipment maintenance companies.** Based on our imaging center business across the country, and the large amount of equipment covering wide geographical regions varied by type and brand, we plan to form strategic cooperations with equipment maintenance companies, to formulate a maintenance system that can match our medical imaging center network and continually reduce our costs.

**Medical imaging AI service providers.** We plan to attract more medical imaging AI service providers to integrate their products into our AI integration platform, thereby enriching our AI offerings and enhancing our service capabilities. Furthermore, we plan to use our professional resources to collaborate with AI service providers to incorporate AI algorithms into doctors' daily medical practice to meet their demands while also helping such algorithms to learn and evolve by themselves.

**Industry associations.** We intend to strengthen our multidimensional professional capabilities by partnering with industry associations in fields including talent development, medical imaging professional capacity assessment, operation and management systems, and medical imaging data standards.

We are also actively monitoring acquisition or investment opportunities related to medical imaging services to continuously expand our service coverage, improve our service capabilities, and broaden our service scope.





## Management Discussion and Analysis

We are interested in the following opportunities:

- Investing in or incubating health management companies to build a medical imaging service platform for commercial clients and individual customers, enriching our products and services and expanding our business outreach.
- Investing in or incubating companies that complement our existing business in areas of cloud services, AI, and big data applications.
- Investing in or incubating companies with advanced technology or R&D capabilities in medical imaging software, hardware or service development for commercialization.

### ***Support of Favorable Government Policies***

In recent years, China has issued a series of favorable policies aiming at deepening the reform of the medical and healthcare system, optimizing medical services and promoting the healthy development of the medical industry, from the “Opinions of the State Council on Promoting the Development of the Healthcare Service Industry 《國務院關於促進健康服務業發展的若干意見》” in 2013 to the “Basic Standards and Management Norms for Medical Image Diagnostic Centers (for Trial Implementation) 《醫學影像診斷中心基本標準和管理規範(試行)》” issued by the National Health and Family Planning Commission in 2016, which formally clarified the status of third-party diagnostic imaging centers as “independent legal persons” throughout the country. In the past ten years, the policy has been centered on the reform and innovation of “strengthening the grassroots, hierarchical diagnosis and treatment, close medical consortium (sharing mechanism) and mutual recognition of results (強基層、分級診療、緊密醫聯體(共享機制)及結果互認)”. The business development model of our Group is highly integrated with the development strategy of the country and the general policy of medical and healthcare system reform, which provides a good opportunity for the high-speed and high-quality development of our Group.

## Management Discussion and Analysis

Throughout the first half of 2024, from the Notice on Further Improving the Mechanism to Promote the Sinking of Urban Medical Resources to County Hospitals and Urban and Rural Grassroots Levels 《關於進一步健全機制推動城市醫療資源向縣級醫院和城鄉基層下沉的通知》 issued by the National Healthcare Commission on June 3, 2024 to, one month later, the Decision of the Central Committee of the Communist Party of China on Further Comprehensively Deepening Reforms and Promoting Chinese-Style Modernization 《中共中央關於進一步全面深化改革、推進中國式現代化的決定》 passed by the Third Plenary Session of the Twentieth Central Committee of the Communist Party of China on July 8, 2024, the relevant policies have successively mentioned promoting the expansion and downward penetration and balanced distribution of high-quality medical resources, accelerating the construction of a hierarchical diagnosis and treatment system, promoting the construction of close-knit medical consortiums, strengthening primary medical and healthcare services, improving the management level of county hospitals, upgrading the service capacity of county hospitals, speeding up the cultivation of a professional talent echelon as well as promoting resource sinking. Focusing on the core of “medical imaging service”, we focus on solving the different needs of “resources, specialty, management, informatization and intelligence” required for the development of medical imaging in China. Through the synergy of the three key business segments, we have extended our business network from first- and second-tier cities to county-level divisions, actively practiced the government’s healthcare reform policy, provided high-quality diagnostic imaging services for primary healthcare institutions, and effectively enhanced the capacity of primary healthcare services.

We have (i) flagship imaging centers; (ii) regional collaborative imaging centers, the concept of which being the most representative model of our imaging centers, which is established in accordance with the “Basic Standards for Medical Imaging Diagnostic Centers (Trial Implementation) 《醫學影像診斷中心基本標準(試行)》” issued by the National Health and Family Planning Commission in 2016, with the qualification of independent legal person. Such regional collaborative imaging center integrates professional imaging centers in the relevant region through the distributed placement of imaging equipments, multi-disciplinary practice of doctors, to integrate professional imaging resources in the relevant region and realize the sharing of data, equipment and professionals. Through resource sharing, equipment sharing, talent sharing and data sharing, we realized effective allocation of resources and promoted the implementation of the national hierarchical diagnosis and treatment system. At the same time, by entering the clinic, serving the clinic and leading the clinic, we promoted the interaction between, and the spiral development of, the clinic and the imaging, so as to lead to the overall high-quality development of the medical institutions, relieve the worries of the



## Management Discussion and Analysis

government, promote the development of the hospitals and benefit the people. At the same time, through (iii) specialized medical consortium imaging centers; and (iv) operational management imaging centers, the imaging capabilities will be transmitted downward to the primary level, covering and extending to areas with insufficient primary level medical imaging resources, and ultimately realize the “one network structure of medical imaging in China” of specialized medical consortiums and medical communities.

On the basis of the imaging center services, we continue to adhere to the output of the four core imaging capabilities (management capability, informatization and intelligence capability, design and construction capability and the imaging professional capacity made by equipment capability, technician operation capability, diagnostic capability of imaging doctors, and cognitive capability of clinicians), which comprehensively affects the center’s and even the hospital’s professional development and level of efficiency, further expands the output of the “professional capability of medical imaging services” that grows out of the self-owned and self-operated imaging centers, and rapidly expands the scope of influence of our imaging capabilities in the form of imaging solution services.

With heavy assets and light assets, we have keenly laid out our digital and intellectual strengths into the whole process of medical imaging services, using data to drive entity operation and service product innovation. Responding to the policy call for “digitalization + intelligence”, in addition to the use of the Internet characteristics of the upper advantage of medical imaging medical resources and services, we continue to take root at the grassroots level to convey the ability to nutrients, but also disassembled the chain of imaging examination link, empowers the roots of the tree through AI to each clinician, imaging technicians and managers. The power of data is used to drive the operation of centers at all levels and the product innovation.

Closely adhering to the national policy, we will actively grasp the elements of new productivity, and through technology innovation, utilize artificial intelligence and other cutting-edge technologies to continuously improve the ability of medical imaging examination and diagnosis. At the same time, through continuous innovation of business model, we actively participate in the deepening of the reform of state-owned enterprises, and synergize in capital, industrial chain, common supply chain and scientific and technological innovation. We believe that this will lay a solid foundation for the sustainable development of our Group and will usher in greater development.

## Corporate Governance and Other Information

### PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

Since the Listing Date and up to June 30, 2024, none of the members of the Group has purchased, sold or redeemed any of the Company's listed securities (including sale of treasury Shares). As at the end of the Reporting Period, the Company did not hold any treasury Shares.

### USE OF NET PROCEEDS FROM THE GLOBAL OFFERING

The Company completed the Global Offering of an aggregate of 17,816,000 H Shares at HK\$14.98 per H Share on June 7, 2024. The net proceeds from the Global Offering amounted to approximately HK\$183.48 million. The net proceeds from the Global Offering in accordance have been and will continue to be used in a manner consistent with that disclosed in the section headed "Future Plans and Use of Proceeds" in the Prospectus, as follows:

Intended utilization	Approximately % of total net proceeds	Net proceeds (HK\$' million)			Expected timeline for unutilized amount
		Actual amount of net proceeds	Utilized amount as of June 30, 2024	Unutilized amount as of June 30, 2024	
For expanding our medical imaging center network	50.0%	91.73	26.70	65.03	To be utilized by December 31, 2025
For pursuing strategic cooperation and mergers and acquisitions in the medical imaging field and seeking strategic partnerships and investment opportunities along the medical imaging services industry chain	20.0%	36.70	8.62	28.08	To be utilized by December 31, 2025
For extending our business to overseas countries and regions which (i) are relatively lacking in medical resources, such as Southeast Asia, and (ii) have high per capital disposable income and great growth potential for medical imaging services, such as the Middle East	20.0%	36.70	2.15	34.55	To be utilized by December 31, 2025

## Corporate Governance and Other Information

Intended utilization	Approximately % of total net proceeds	Net proceeds (HK\$' million)			Expected timeline for unutilized amount
		Actual amount of net proceeds	Utilized amount as of June 30, 2024	Unutilized amount as of June 30, 2024	
Working capital and general corporate uses	10.0%	18.35	0	18.35	To be utilized by December 31, 2025
Total	100%	183.48	37.48	146.00	To be utilized by December 31, 2025

It is expected that all remaining unutilized net proceeds will be fully utilized by December 31, 2025. The expected timing of the utilization of the remaining proceeds is based on the Group's view that such timing will vary depending on current and future developments in market conditions.

### CORPORATE GOVERNANCE

The Company recognises the importance of good corporate governance for enhancing the management of the Company as well as preserving the interests of the Shareholders as a whole. The Company has adopted corporate governance practices based on the principles and code provisions as set out in the Corporate Governance Code and has complied with all applicable code provisions since the Listing Date and up to June 30, 2024.

### MODEL CODE FOR SECURITIES TRANSACTIONS BY THE DIRECTORS AND SUPERVISORS

The Company has adopted the Model Code as its code of conduct regarding dealings in the securities of the Company by the Directors and the Supervisors who, because of his/her office or employment, is likely to possess inside information in relation to the Group or the Company's securities.



## Corporate Governance and Other Information

Upon specific enquiry, all Directors and Supervisors confirmed that they have complied with the Model Code since the Listing Date and up to June 30, 2024. In addition, the Company is not aware of any non-compliance with the Model Code by the members of senior management of the Company since the Listing Date and up to June 30, 2024.

### EVENTS AFTER THE REPORTING PERIOD

There is no material subsequent events after the Reporting Period and up to the date of the Interim Results Announcement.

### REVIEW OF INTERIM RESULTS

The Audit Committee consists of three members, including two independent non-executive Directors, namely Mr. WU Xiaohui (吳曉輝) and Mr. YUAN Jun (袁駿), and one non-executive Director, namely Mr. LIU Senlin (劉森林). The chairman of the Audit Committee is Mr. WU Xiaohui (吳曉輝) who holds the appropriate qualification as required under Rules 3.10(2) and 3.21 of the Listing Rules.

The Audit Committee has reviewed the unaudited condensed consolidated interim financial information of the Group for the six months ended June 30, 2024 with the management of the Company. The Audit Committee considered that the interim results are in compliance with the applicable accounting standards, laws and regulations, and the Company has made appropriate disclosures thereof. The Audit Committee has also discussed matters with respect to the accounting policies and practices adopted by the Company and internal control with senior management of the Company.

### INTERIM DIVIDEND

The Board does not recommend the distribution of any interim dividend for the Reporting Period.

### CHANGE OF INFORMATION OF DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT MEMBERS

Since the date of the Prospectus and up to the date of the Interim Results Announcement, there was no change to information which was required to be disclosed by Directors, Supervisors and senior management members pursuant to Rule 13.51B(1) of the Listing Rules.



## Corporate Governance and Other Information

### **DIRECTORS' AND SUPERVISORS' RIGHT TO PURCHASE SHARES OR DEBENTURES**

As at the end of the Reporting Period, none of the Directors, Supervisors or their respective spouses or minor children under the age of 18 years were granted with rights, or had exercised any such rights, to acquire benefits by means of purchasing Shares or debentures of the Company. No member of the Group was a party to any arrangements to enable the Directors, Supervisors or their respective spouses or minor children under the age of 18 years to acquire such rights from any other body corporates.

During the six months ended June 30, 2024, the Company did not grant any rights to acquire benefits by means of the acquisition of Shares or debentures of the Company to any Directors or Supervisors or their respective spouses or minor children under 18, and none of them has exercised such rights.

### **DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS**

As at June 30, 2024, the interests or short positions of the Directors, Supervisors and chief executives of the Company in the Shares, underlying Shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) which were required (a) to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which any such Directors, Supervisors and chief executive(s) of the Company are taken or deemed to have under such provisions of the SFO); or (b) to be entered in the register required to be kept by the Company pursuant to Section 352 of the SFO; or (c) as otherwise notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code were as follows:

## Corporate Governance and Other Information

### (a) Interest in Shares

Name	Position in the Company	Nature of interest	Number and type of Shares held <sup>(1)</sup>	Approximate percentage of the relevant type of Shares <sup>(1)</sup> (%)	Approximate percentage of the total issued Shares <sup>(1)</sup> (%)
CHEN Zhaoyang (陳朝陽) <sup>(2)</sup>	Executive Director and Chief	Interest in controlled corporation	18,213,291 H Shares (L)	9.21	5.11
	Executive Officer	Interest in controlled corporation	40,875,297 Unlisted Shares (L)	25.79	11.47

Notes:

- (1) The table above is calculated based on the total number of 356,311,832 Shares (comprising 158,495,832 Unlisted Shares and 197,816,000 H Shares) in issue as at June 30, 2024.
- (2) As of June 30, 2024, Nanchang Rimag, the Company's employee incentive platform, directly held 59,088,588 Shares (comprising 18,213,291 H Shares and 40,875,297 Unlisted Shares), whose general partner is CHEN Zhaoyang. Therefore, Mr. Chen is deemed to be interested in the 59,088,588 Shares held by Nanchang Rimag for the purpose of Part XV of the SFO.
- (L) Long position.

## Corporate Governance and Other Information

### (b) Interest in Associated Corporations

Name	Position in the Company	Associated corporation	Nature of Interest	Registered capital held in the associated corporation	Approximate percentage of the total registered capital of the associated corporation (%)
XU Ke (徐克)	Chairman of the Board and Executive Director	Liaoning Rimag Medical Imaging Diagnosis Center Co., Ltd. (遼寧一脈陽光醫學影像診斷中心有限公司) <sup>(1)</sup>	Beneficial owner	RMB500,000	5%

Note:

- (1) As at June 30, 2024, Liaoning Rimag Medical Imaging Diagnosis Center Co., Ltd (遼寧一脈陽光醫學影像診斷中心有限公司), a subsidiary of the Company, had a total of RMB10,000,000 registered capital.

Save as disclosed above, as at June 30, 2024, to the best of the Company's knowledge, information and belief, none of the Directors, Supervisors and chief executives of the Company had or was deemed to have any interests or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required (a) to be notified to the Company and the Hong Kong Stock Exchange pursuant to Division 7 and 8 of Part XV of the SFO; or (b) to be entered in the register required to be kept by the Company pursuant to Section 352 of the SFO; or (c) as otherwise to be notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code.

## Corporate Governance and Other Information

### SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

As at June 30, 2024, to the best knowledge of the Directors or chief executives of the Company, the interests or short positions of the following persons (other than the Directors, Supervisors and chief executives of the Company) in the Shares, underlying Shares of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 2 and 3 of Part XV of the SFO (including interests or short positions which any such persons other than the Directors, Supervisors and chief executives of the Company are taken or deemed to have under such provisions of the SFO), or which were required to be entered in the register required to be kept by the Company pursuant to Section 336 of the SFO were as follows:

Name of Shareholder	Nature of Interest	Number and type of Shares held <sup>(1)</sup>	Approximate percentage of the relevant type of Shares <sup>(1)</sup> (%)	Approximate percentage of total issued Shares <sup>(1)</sup> (%)
Nanchang Rimag <sup>(2)</sup>	Beneficial Interest	18,213,291 H Shares (L)	9.21	5.11
		40,875,297 Unlisted Shares (L)	25.79	11.47
Beijing Goldman Sachs Consulting Co., Ltd. (北京高盛顧問有限公司) <sup>(3)</sup>	Beneficial interest	30,882,270 H Shares (L)	15.61	8.67
Goldman Sachs Holding (Mauritius) Limited <sup>(3)</sup>	Interest in controlled corporation	30,882,270 H Shares (L)	15.61	8.67
Tiger Strategic Investments Ltd. <sup>(3)</sup>	Interest in controlled corporation	30,882,270 H Shares (L)	15.61	8.67
GS Asian Venture (Delaware) L.L.C. <sup>(3)</sup>	Interest in controlled corporation	30,882,270 H Shares (L)	15.61	8.67
Goldman Sachs & Co. LLC <sup>(3)</sup>	Interest in controlled corporation	30,882,270 H Shares (L)	15.61	8.67



## Corporate Governance and Other Information

Name of Shareholder	Nature of Interest	Number and type of Shares held <sup>(1)</sup>	Approximate percentage of the relevant type of Shares <sup>(1)</sup> (%)	Approximate percentage of total issued Shares <sup>(1)</sup> (%)
Special Situations Investing Group III, Inc. <sup>(3)</sup>	Interest in controlled corporation	30,882,270 H Shares (L)	15.61	8.67
GSSG Holdings LLC <sup>(3)</sup>	Interest in controlled corporation	30,882,270 H Shares (L)	15.61	8.67
The Goldman Sachs Group, Inc. <sup>(3)</sup>	Interest in controlled corporation	30,882,270 H Shares (L)	15.61	8.67
PICC Beijing Health Care Fund, L.P. (北京人保健康養老產業投資基金(有限合夥)) <sup>(4)</sup>	Beneficial Interest	19,289,403 H Shares (L)	9.75	5.41
PICC Capital Equity Investment Co., Ltd. (人保資本股權投資有限公司) <sup>(4)</sup>	Interest in controlled corporation	19,289,403 H Shares (L)	9.75	5.41
PICC Life Insurance Company Limited (中國人民人壽保險股份有限公司) <sup>(4)</sup>	Interest in controlled corporation	19,289,403 H Shares (L)	9.75	5.41
PICC Property and Casualty Company Limited (中國人民財產保險股份有限公司) <sup>(4)</sup>	Interest in controlled corporation	19,289,403 H Shares (L)	9.75	5.41
The People's Insurance Company (Group) of China Limited (中國人民保險集團股份有限公司) <sup>(4)</sup>	Interest in controlled corporation	19,289,403 H Shares (L)	9.75	5.41
Ningbo Meishan Free Trade Port Zone Baishan Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區佰山投資管理合夥企業(有限合夥)) <sup>(5)</sup>	Beneficial Interest	17,647,051 Unlisted Shares (L)	11.13	4.95
Ningbo Meishan Free Trade Port Zone Baiyi Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區佰毅投資管理合夥企業(有限合夥)) <sup>(5)</sup>	Interest in controlled corporation	17,647,051 Unlisted Shares (L)	11.13	4.95
Ningbo Meishan Free Trade Port Zone Baining Investment Partnership (Limited Partnership) (寧波梅山保稅港區佰寧投資合夥企業(有限合夥)) <sup>(5)</sup>	Interest in controlled corporation	17,647,051 Unlisted Shares (L)	11.13	4.95
Baidu, Inc. (百度集團股份有限公司) <sup>(5)</sup>	Interest in controlled corporation	17,647,051 Unlisted Shares (L)	11.13	4.95
China Life Insurance Company Limited (中國人壽保險股份有限公司) <sup>(5)</sup>	Interest in controlled corporation	17,647,051 Unlisted Shares (L)	11.13	4.95
Ganjiang New Area Development and Investment Group Co., Ltd. (贛江新區創新產業投資有限公司) <sup>(6)</sup>	Beneficial interest	14,558,319 Unlisted Shares (L)	9.19	4.09

## Corporate Governance and Other Information

Name of Shareholder	Nature of Interest	Number and type of Shares held <sup>(1)</sup>	Approximate percentage of the relevant type of Shares <sup>(1)</sup> (%)	Approximate percentage of total issued Shares <sup>(1)</sup> (%)
Ganjiang New Area Urban Construction Industry Co., Ltd. (贛江新區城市建設實業有限公司) <sup>(6)</sup>	Interest in controlled corporation	14,558,319 Unlisted Shares (L)	9.19	4.09
Ganjiang Holdings Group Co., Ltd. (贛江控股集團有限公司) <sup>(6)</sup>	Interest in controlled corporation	14,558,319 Unlisted Shares (L)	9.19	4.09
Jiangxi Province Investment Group Co., Ltd. (江西省投資集團有限公司) <sup>(6)</sup>	Interest in controlled corporation	14,558,319 Unlisted Shares (L)	9.19	4.09
State-owned Asset Supervision and Administration Commission of Jiangxi Province (江西省國有資產監督管理委員會) <sup>(6)</sup>	Interest in controlled corporation	16,055,834 Unlisted Shares (L)	10.13	4.51
GU Junjun	Beneficial interest	9,758,849 Unlisted Shares (L)	6.16	2.74
WANG Shihe	Beneficial interest	9,755,070 Unlisted Shares (L)	6.15	2.74
Jiangxi Fenyong Technology Service Co., Ltd. (江西奮勇科技服務有限公司) <sup>(7)</sup>	Beneficial interest	9,317,271 Unlisted Shares (L)	5.88	2.61
Zhejiang Jinke Tom Culture Industry Co., Ltd. (浙江金科湯姆貓文化產業股份有限公司) <sup>(7)</sup>	Interest in controlled corporation	9,317,271 Unlisted Shares (L)	5.88	2.61
Suqian JD Yingzheng Enterprise Management Consulting Co., Ltd. (宿遷京東盈正企業管理諮詢有限公司) <sup>(8)</sup>	Beneficial interest	8,175,910 Unlisted Shares (L)	5.16	2.29
JD Health International Inc. <sup>(8)</sup>	Interest in controlled corporation	8,175,910 Unlisted Shares (L)	5.16	2.29
JD Jiankang Limited <sup>(8)</sup>	Interest in controlled corporation	8,175,910 Unlisted Shares (L)	5.16	2.29
JD.com, Inc. <sup>(8)</sup>	Interest in controlled corporation	8,175,910 Unlisted Shares (L)	5.16	2.29
Max Smart Limited <sup>(8)</sup>	Interest in controlled corporation	8,175,910 Unlisted Shares (L)	5.16	2.29
Liu Qiangdong Richard (劉強東) <sup>(8)</sup>	Beneficiary of a trust	8,175,910 Unlisted Shares (L)	5.16	2.29
UBS Trustees (B.V.I) Limited <sup>(8)</sup>	Trustee	8,175,910 Unlisted Shares (L)	5.16	2.29

## Corporate Governance and Other Information

### Notes:

- (1) The table above is calculated based on the total number of 356,311,832 Shares (comprising 158,495,832 Unlisted Shares and 197,816,000 H Shares) in issue as at June 30, 2024.
- (2) As of June 30, 2024, Nanchang Rimag, the Company's employee incentive platform, directly held 59,088,588 Shares (comprising 18,213,291 H Shares and 40,875,297 Unlisted Shares), whose general partner is CHEN Zhaoyang. Therefore, Mr. Chen is deemed to be interested in the 59,088,588 Shares held by Nanchang Rimag for the purpose of Part XV of the SFO.
- (3) As of June 30, 2024, Beijing Goldman Sachs Consulting Co., Ltd. (北京高盛顧問有限公司) directly held 30,882,270 H Shares, which is 100% controlled by Goldman Sachs Holdings (Mauritius) Limited. Goldman Sachs Holdings (Mauritius) Limited is 100% controlled by Tiger Strategic Investments Ltd., which is in turn 92% controlled by GS Asian Venture (Delaware) L.L.C.. GS Asian Venture (Delaware) L.L.C. is 100% controlled by Goldman Sachs & Co. LLC and also 100% controlled by Special Situations Investing Group III, Inc (which is in turn 100% controlled by GSSG Holdings LLC). Both Goldman Sachs & Co. LLC and GSSG Holdings LLC are 100% controlled by The Goldman Sachs Group, Inc..
- (4) As of June 30, 2024, PICC Beijing Health Care Fund, L.P. (北京人保健康養老產業投資基金(有限合夥)) directly held 19,289,403 H Shares, which is controlled as to 66.47%, 33.23% and 100% by PICC Life Insurance Company Limited (中國人民人壽保險股份有限公司), PICC Property and Casualty Company Limited (中國人民財產保險股份有限公司) and PICC Capital Equity Investment Co., Ltd. (人保資本股權投資有限公司) (as its general partner), respectively. PICC Capital Equity Investment Co., Ltd. (人保資本股權投資有限公司) is 100% controlled by PICC Capital Insurance Asset Management Co., Ltd. (人保資本保險資產管理有限公司). Each of PICC Life Insurance Company Limited (中國人民人壽保險股份有限公司), PICC Property and Casualty Company Limited (中國人民財產保險股份有限公司) and PICC Capital Insurance Asset Management Co., Ltd. (人保資本保險資產管理有限公司) is controlled by The People's Insurance Company (Group) of China Limited (中國人民保險集團股份有限公司) as to 71.08%, 68.98% and 100%, respectively.
- (5) As of June 30, 2024, Ningbo Meishan Free Trade Port Zone Baishan Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區佰山投資管理合夥企業(有限合夥)) directly held 17,647,051 Unlisted Shares, which is 79.77% controlled by Ningbo Meishan Free Trade Port Zone Baining Investment Partnership (Limited Partnership) (寧波梅山保稅港區佰寧投資合夥企業(有限合夥)) and also 100% controlled by Ningbo Meishan Free Trade Port Zone Baiyi Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區佰毅投資管理合夥企業(有限合夥)). Ningbo Meishan Free Trade Port Zone Baining Investment Partnership (Limited Partnership) (寧波梅山保稅港區佰寧投資合夥企業(有限合夥)) is in turn 99.98% controlled by China Life Insurance Company Limited (中國人壽保險股份有限公司). Ningbo Meishan Free Trade Port Zone Baiyi Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區佰毅投資管理合夥企業(有限合夥)) is in turn 60% controlled by Baidu, Inc. (百度集團股份有限公司).

## Corporate Governance and Other Information

- (6) As of June 30, 2024, Ganjiang New Area Development and Investment Group Co., Ltd. (贛江新區創新產業投資有限公司) directly held 14,558,319 Unlisted Shares. It is 100% controlled by Ganjiang New Area Urban Construction Industry Co., Ltd. (贛江新區城市建設實業有限公司), which is in turn 100% controlled by Ganjiang Holdings Group Co., Ltd. (贛江控股集團有限公司), a company 90% controlled by Jiangxi Province Investment Group Co., Ltd. (江西省投資集團有限公司). Jiangxi Province Investment Group Co., Ltd. (江西省投資集團有限公司) is 90% controlled by the State-owned Asset Supervision and Administration Commission of Jiangxi Province (江西省國有資產監督管理委員會). In addition, the State-owned Asset Supervision and Administration Commission of Jiangxi Province (江西省國有資產監督管理委員會) is also interested in 1,497,515 Unlisted Shares through its 90% controlled Jiangxi Provincial State-owned Enterprise Asset Management (Holding) Co., Ltd. (江西省國有資本運營控股集團有限公司).
- (7) As of June 30, 2024, Jiangxi Fenyong Technology Service Co., Ltd. (江西奮勇科技服務有限公司) directly held 9,317,271 Unlisted Shares, a company controlled by Zhejiang Jinke Tom Culture Industry Co., Ltd. (浙江金科湯姆貓文化產業股份有限公司).
- (8) As of June 30, 2024, Suqian JD Yingzheng Enterprise Management Consulting Co., Ltd. (宿遷京東盈正企業管理諮詢有限公司) directly held 8,175,910 Unlisted Shares. It is 100% controlled by JD Health International Inc., which is in turn 67.40% controlled by JD Jiankang Limited. JD Jiankang Limited is 100% controlled by JD.com, Inc., which is in turn 70.50% controlled by Max Smart Limited and Fortune Rising Holdings Limited. Max Smart Limited is 100% controlled by Liu Qiangdong Richard (劉強東), in the capacity as a beneficiary of a trust. Max Smart Limited is also 100% controlled by UBS Trustees (B.V.I.) Limited, in the capacity as a trustee, through its 100% controlled UBS Nominees Limited.
- (L) Long position.

Save as disclosed above, as at June 30, 2024, no person (other than the Directors, Supervisor and chief executives of the Company had or was deemed to have any interests or short positions in the shares, underlying shares of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified the Company or the Hong Kong Stock Exchange pursuant to Divisions 2 and 3 of Part XV of the SFO or which were required to be entered in the register required to be kept by the Company pursuant to Section 336 of the SFO.)

### PRE-IPO EMPLOYEE INCENTIVE SCHEME

The Company has adopted the 2021 Share Incentive Scheme (the “Scheme”) by a resolution of our Shareholders in November 2021. As of June 30, 2024, 20,000,001 Shares subject to the Scheme were held by Nanchang Rimag, the employee incentive platform, representing approximately 5.61% of the aggregate amount of the Shares in issue. The Scheme is not subject to the provisions of Chapter 17 of the Listing Rules as all the award granted pursuant to the Scheme have been vested and no new option or awards will be granted by our Company under the Scheme after the Listing.

## Corporate Governance and Other Information

The following is a summary of the principal terms of the Scheme:

### 1. Summary of terms

**(a) Purposes of the Scheme**

The purposes of the Scheme are to recognize the contributions of and retain our key employees and motivate them to further promote the development of the Group.

**(b) Awards**

An award under the Scheme (the “Award(s)”) gives a participant in the Scheme a conditional right when granted the Award to obtain interests in Nanchang Rimag, as determined by the administrative office of the Board (董事會辦公室) (the “Board Office”) and approved by the shareholders.

**(c) Number of Underlying Shares Subject to the Scheme**

The number of Shares held by Nanchang Rimag under the Scheme is 20,000,001 Shares.

**(d) Participants**

Participants of the Scheme (the “Participants”) are selected by the Board Office from the senior- and middle-level management, core employees and other employees who are deemed to have influence on the business performance and future development of the Company and should be subject to the Scheme of the Group.

**(e) Term of the Scheme**

The provisions of the Scheme shall in all aspects remain in full force and effect from the date of granting the Awards until the date of full exercise of all the Awards under the Scheme.

All the Awards granted to the Participants under the Scheme shall continue to be held by Nanchang Rimag and become vested in the Participants according to the conditions under the Scheme.

**(f) Grant and Acceptance of Award**

On and subject to the limitations and conditions of the Scheme, the list of Participants, the number of Awards to be granted, the grant price and the lock-up period shall be determined by the Board Office and subject to the approval of the Shareholders and the number of Awards to be granted may differ among selected Participants.



## Corporate Governance and Other Information

After the Board Office has decided to make a grant of Awards to any Participant, the Participant and the Company shall enter into a share incentive agreement, which set out the number of Awards so granted and the conditions (if any) upon which such Awards were granted and the lock-up period.

**(g) *Rights Attached to the Awards***

A Participant shall have right to receive dividend in the Awards after the date on which such Awards are granted and prior to the date on which such Awards are vested.

**(h) *Awards to Be Personal to the Participants***

Prior to the date of vesting of the Awards to the Participant, any Award made under the Scheme shall be personal to the Participant to whom it is made and shall not be assignable and no Participant shall in any way sell, transfer, charge, mortgage, encumber or create any interest in favor of any other person over or in relation to the Awards referable to him pursuant to such Award.

**(i) *Repurchase of Award***

Any unvested Awards shall be unconditionally repurchased by the Company or an entity the Board Office designated (the “Designated Person”) where (i) such Participant’s employment or service with the Group is changed or terminated due to his/her incompetency, violation of moral codes or laws, breach of confidentiality obligation, dereliction of duty or malfeasance or material violation of protocols of the Company; or (ii) such Participant’s employment or service with the Group is terminated due to his voluntary resignation, dismissal, laid-off, termination of employment relationship.

If the Participant’s employment or service with the Group is terminated by reason of death or disability, in terms of any unvested Awards, (i) in the event of work injuries, the Awards will be vested immediately to the Participant pursuant to the Scheme; (ii) in the event of non-work injuries, the Awards will be vested partially based on the Participant’s contribution to the Group as determined by the Board Office, and the rest of the Awards will be repurchased by the Designated Person; (iii) in the event of death, the Awards will be vested immediately to the legal heir of the Participants pursuant to the Scheme.

**(j) *Takeovers and Mergers and Demerger***

Any event of change in control or merger, or demerger will not affect the implementation of the Scheme.

## Corporate Governance and Other Information

**(k) Amendment of the Scheme**

The Scheme may be amended in any respect as determined by the Board Office, subject to the condition that such amendment shall not accelerate the expiration date of the lock-up period or lower the grant price of the Awards.

**(l) Administration of the Scheme**

The Scheme shall be subject to the administration of the Board Office in accordance with the rules of the Scheme, including the power to amend, implement and construe and interpret the rules of the Scheme and the terms of the Awards granted under it.

**(m) Termination of the Scheme**

The Scheme will terminate on the date of full release of all the restricted shares under the Scheme.

### 2. Incentive Shares Granted

All Shares underlying the Awards (i.e. 20,000,001 Shares) were transferred to Nanchang Rimag in August 2022. As at June 30, 2024, all Awards pursuant to the Scheme had been granted and vested to 20 Participants.

## Condensed Consolidated Interim Income Statement

For the six months ended 30 June 2024

	Note	Six months ended 30 June	
		2024 RMB'000	2023 RMB'000
Revenue	6	413,713	529,779
Cost of sales		(254,054)	(341,148)
<b>Gross profit</b>		159,659	188,631
Selling expenses		(32,961)	(34,500)
Administrative expenses		(111,092)	(81,102)
Research and development expenses		(5,715)	(5,881)
Net impairment losses on financial assets		(1,364)	(4,169)
Other income		5,152	4,969
Other gains – net		1,699	5,131
Operating profit	7	15,378	73,079
Finance income	8	1,143	1,970
Finance costs	8	(11,049)	(12,628)
<b>Finance costs – net</b>		(9,906)	(10,658)
Share of loss of investments accounted for using the equity method		(1,098)	(5,740)
Impairment losses on investment in the joint venture accounted for using the equity method		–	(1,534)
<b>Profit before income tax</b>		4,374	55,147
Income tax expense	9	(3,412)	(7,855)
<b>Profit for the period</b>		962	47,292
<b>Profit for the period attributable to:</b>			
Owners of the Company		3,836	42,979
Non-controlling interests		(2,874)	4,313
		962	47,292
<b>Profit per share attributable to owners of the Company for the period</b>			
Basic (expressed in RMB per share)	10	0.011	0.127
Diluted (expressed in RMB per share)	10	0.011	0.127

The notes on pages 45 to 82 form an integral part of this condensed consolidated interim financial information.

## Condensed Consolidated Interim Statement of Comprehensive Income

For the six months ended 30 June 2024

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
<b>Profit for the period</b>	962	47,292
<i>Items that may be reclassified to profit or loss</i>		
Changes in the fair value of debt instruments at fair value through other comprehensive income	(2)	(50)
<b>Other comprehensive income for the period, net of tax</b>	(2)	(50)
<b>Total comprehensive income for the period</b>	960	47,242
<b>Total comprehensive income for the period attributable to:</b>		
Owners of the Company	3,834	42,929
Non-controlling interests	(2,874)	4,313
	960	47,242

The notes on pages 45 to 82 form an integral part of this condensed consolidated interim financial information.

## Condensed Consolidated Interim Statements of Financial Position

As at 30 June 2024

	Note	As at 30 June 2024 RMB'000	As at 31 December 2023 RMB'000
<b>Assets</b>			
<b>Non-current assets</b>			
Property, plant and equipment	11	770,033	741,122
Right-of-use assets	11	154,899	159,904
Intangible assets	11	44,916	46,214
Deferred income tax assets		32,080	24,208
Investments accounted for using the equity method	12	29,662	30,760
Prepayments, deposits and other receivables	15	202,143	132,887
Financial asset at fair value through other comprehensive income	13	–	4,772
Financial assets at fair value through profit or loss	16	59,093	53,869
Long-term trade receivables	14	60,473	58,339
Restricted cash		4,105	6,104
<b>Total non-current assets</b>		<b>1,357,404</b>	<b>1,258,179</b>
<b>Current assets</b>			
Financial assets at fair value through other comprehensive income	13	2,494	3,491
Inventories		5,163	5,333
Long-term trade receivables – current portion	14	25,512	23,232
Trade receivables	14	407,264	308,796
Prepayments, deposits and other receivables	15	70,900	86,087
Restricted cash		2	2
Cash and cash equivalents		305,535	188,835
Asset classified as held for sale		4,703	4,703
<b>Total current assets</b>		<b>821,573</b>	<b>620,479</b>
<b>Total assets</b>		<b>2,178,977</b>	<b>1,878,658</b>



## Condensed Consolidated Interim Statements of Financial Position

As at 30 June 2024

	Note	As at 30 June 2024 RMB'000	As at 31 December 2023 RMB'000
<b>EQUITY</b>			
<b>Equity attributable to owners of the Company</b>			
Share capital	17	356,312	338,496
Reserves	18	1,612,011	1,401,974
Accumulated losses		(444,007)	(447,843)
<b>Equity attributable to owners of the Company</b>		<b>1,524,316</b>	<b>1,292,627</b>
<b>Non-controlling interests</b>		<b>38,788</b>	<b>42,487</b>
<b>Total equity</b>		<b>1,563,104</b>	<b>1,335,114</b>
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
Borrowings	22	118,228	84,966
Lease liabilities		119,324	136,280
Deferred income tax liabilities		4,332	4,414
Other non-current liabilities		536	1,700
<b>Total non-current liabilities</b>		<b>242,420</b>	<b>227,360</b>
<b>Current liabilities</b>			
Trade payables	21	41,860	23,482
Other payables and accruals		69,486	75,869
Contract liabilities	6(c)	18,173	8,959
Current tax liabilities		48,751	42,662
Borrowings	22	147,148	125,042
Lease liabilities		47,596	39,731
Other non current liability-current portion		439	439
<b>Total current liabilities</b>		<b>373,453</b>	<b>316,184</b>
<b>Total liabilities</b>		<b>615,873</b>	<b>543,544</b>
<b>Total equity and liabilities</b>		<b>2,178,977</b>	<b>1,878,658</b>

Mr. CHEN Zhaoyang  
Director

Mr. FENG Xie  
Director

The notes on pages 45 to 82 form an integral part of this condensed consolidated interim financial information.

## Condensed Consolidated Interim Statements of Changes in Equity

For the six months ended 30 June 2024

		Equity attributable to owners of the Company					
		Share capital RMB'000	Reserves RMB'000	Accumulated losses RMB'000	Subtotal RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
Note							
	<b>As at 1 January 2024</b>	338,496	1,401,974	(447,843)	1,292,627	42,487	1,335,114
	Profit/(loss) for the period	-	-	3,836	3,836	(2,874)	962
	Other comprehensive loss	-	(2)	-	(2)	-	(2)
	Total comprehensive (loss)/income	-	(2)	3,836	3,834	(2,874)	960
	Capital injection	-	-	-	-	700	700
	Shares issued pursuant to initial public offering on the Main Board of The Stock Exchange of Hong Kong Limited (the "Listing")	17,816	225,147	-	242,963	-	242,963
	Listing expenses capitalised upon the Listing	-	(15,574)	-	(15,574)	-	(15,574)
	Dividend distribution	-	-	-	-	(1,531)	(1,531)
	Share-based payments expenses	-	466	-	466	6	472
	Total transactions with owners	17,816	210,039	-	227,855	(825)	227,030
	<b>As at 30 June 2024</b>	356,312	1,612,011	(444,007)	1,524,316	38,788	1,563,104

## Condensed Consolidated Interim Statements of Changes in Equity

For the six months ended 30 June 2024

Equity attributable to owners of the Company						
	Share capital	Reserves	Accumulated losses	Subtotal	Non-controlling interests	Total equity
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
<b>As at 1 January 2023</b>	338,496	1,426,432	(492,258)	1,272,670	43,569	1,316,239
Profit for the period	-	-	42,979	42,979	4,313	47,292
Other comprehensive loss	-	(50)	-	(50)	-	(50)
Total comprehensive (loss)/income	-	(50)	42,979	42,929	4,313	47,242
Capital injection	-	-	-	-	215	215
Disposal of subsidiaries	-	-	-	-	1,497	1,497
Transactions with non-controlling interests	-	(11,377)	-	(11,377)	(6,623)	(18,000)
Share-based payments expenses	-	1,475	-	1,475	26	1,501
Total transactions with owners	-	(9,902)	-	(9,902)	(4,885)	(14,787)
<b>As at 30 June 2023</b>	338,496	1,416,480	(449,279)	1,305,697	42,997	1,348,694

The notes on pages 45 to 82 form an integral part of this condensed consolidated interim financial information.

## Condensed Consolidated Interim Statements of Cash Flows

For the six months ended 30 June 2024

	Note	Six months ended 30 June	
		2024 RMB'000	2023 RMB'000
<b>Cash flows from operating activities</b>			
Cash used in operations		38,477	101,829
Interest received		927	1,847
Income tax paid		(5,277)	(6,260)
<b>Net cash generated from operating activities</b>		<b>34,127</b>	<b>97,416</b>
<b>Cash flows from investing activities</b>			
Prepayment on equity investments		–	(2,850)
Investments in associates and joint ventures	12	–	(11,280)
Proceeds from disposal of subsidiaries		2,910	123
Proceeds from disposal of investments in joint ventures		1,400	–
Proceeds from disposal of property, plant and equipment		1	1,537
Repayments of loans to third parties		600	–
Purchases of intangible assets		(992)	(6,431)
Purchases of property, plant and equipment		(179,308)	(46,755)
<b>Net cash used in investing activities</b>		<b>(175,389)</b>	<b>(65,656)</b>
<b>Cash flows from financing activities</b>			
Proceeds from initial public offering		242,963	–
Capital injection from non-controlling interests in subsidiaries		700	215
Dividends paid to non-controlling interests of subsidiaries		(1,531)	–
Transaction with non-controlling interests		–	(18,000)
Proceeds from bank borrowings		45,800	10,000
Repayments of bank borrowings		(25,111)	(35,473)
Proceeds from loans from financial leasing companies		74,934	18,483
Repayments of loans from financial leasing companies		(40,280)	(88,856)
Principal elements of lease payments		(21,412)	(5,344)
Listing expense		(9,076)	(2,856)
Decrease/(increase) in restricted cash		1,999	(2,286)
Interest paid		(11,024)	(12,954)
<b>Net cash generated from/(used in) financing activities</b>		<b>257,962</b>	<b>(137,071)</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>116,700</b>	<b>(105,311)</b>
Cash and cash equivalents at the beginning of period		188,835	340,194
<b>Cash and cash equivalents at the end of period</b>		<b>305,535</b>	<b>234,883</b>

The notes on pages 45 to 82 form an integral part of this condensed consolidated interim financial information.

# Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

## 1 GENERAL INFORMATION

Jiangxi Rimag Group Co., Ltd. formerly known as Shenzhen RIMAG Sunshine Medical Technology Co., Ltd. (the “Company”) was incorporated as a limited liability company on 30 October 2014 in Shenzhen, Guangdong Province, People’s Republic of China (the “PRC”). The registered office of the Company is Room 1002, 10th Floor, No. 10 Building Public R&D Centre Xinqi Zhoudong Avenue South Chinese Medicine Science and Technology Innovation City Ganjiang New District Jiangxi Province, PRC. In June 2021, the Company was converted into a joint stock company with limited liabilities. The Company provides medical imaging services through the establishment of medical imaging network, as well as operational management services, imaging solution services and Rimag Cloud services.

The Company and its subsidiaries (collectively, the “Group”) are principally engaged in the providing medical imaging services, imaging solution services and Rimag Cloud services in the PRC.

The Company’s H Shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited since 7 June 2024.

This condensed consolidated interim financial information is presented in thousands of Renminbi (“RMB”), unless otherwise stated, and was approved for issue by the Board of Directors on 27 August 2024.

This condensed consolidated interim financial information has not been audited but has been reviewed by the Audit Committee.

## 2 BASIS OF PREPARATION

This condensed consolidated interim financial information for the six months ended 30 June 2024 has been prepared in accordance with International Accounting Standards (“IAS”) 34, ‘Interim financial reporting’. The condensed consolidated interim financial information should be read in conjunction with the consolidated financial statements for the year ended 31 December 2023, which have been prepared in accordance with IFRS Accounting Standards issued by the International Accounting Standards Board (“IASB”).



## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 3 MATERIAL ACCOUNTING POLICIES

Except for the adoption of new or amended standards and interpretations since 1 January 2024 as described below, the accounting policies applied are consistent with those of the consolidated financial statements for the year ended 31 December 2023, as described in those consolidated financial statements.

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.

#### (a) New and amended standards adopted by the Group

A number of new or amended standards and interpretations became applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting these standards.

New standards and amendments		Effective for annual periods beginning on or after
IAS 1 (Amendments)	Classification of liabilities as current or non-current	1 January 2024
IAS 1 (Amendments)	Non-current liabilities with covenants	1 January 2024
IFRS 16 (Amendments)	Lease liability in sale and leaseback	1 January 2024
IAS 7 and IFRS 7 (Amendments)	Supplier finance arrangements	1 January 2024

#### (b) New standards and amendments not yet adopted

The following new standards, new interpretations and amendments to standards and interpretations have been issued but are not effective for the financial year beginning on 1 January 2024 and have not been early adopted by the Group:

New standards and amendments		Effective for annual periods beginning on or after
IAS 21 (Amendments)	Lack of exchangeability	1 January 2025
IFRS 9 and IFRS 7 (Amendments)	Amendments to the classification and measurement of financial instruments	1 January 2026
Annual improvements project	Annual improvements to IFRS Accounting Standards – volumes 11	1 January 2026
IFRS 18	Presentation and disclosure in financial statements	1 January 2027
IFRS 19	Subsidiaries without public accountability: disclosures	1 January 2027
IFRS 10 and IAS 28 (Amendments)	Sale or contribution of assets between an investor and its associate or joint venture	To be determined

The Group is assessing the full impact of the new standards, new interpretations and amendments to standards and interpretations.

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 4 ESTIMATES

The preparation of interim financial information requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing this condensed consolidated interim financial information, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements for the year ended 31 December 2023.

### 5 FINANCIAL RISK MANAGEMENT

#### 5.1 Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risks and cash flow and fair value interests rate risk), credit risk and liquidity risk.

The condensed consolidated interim financial information does not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's consolidated financial statements as at 31 December 2023.

There have been no changes in the major risk management policies since the year end.

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 5 FINANCIAL RISK MANAGEMENT *(continued)*

#### 5.2 Liquidity risk

The tables below analyse the Group's non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the end of each reporting period to the contractual maturity date. The amounts disclosed in the tables are the contractual undiscounted cash flows.

	Less than 1 year RMB'000	Between 1 and 2 years RMB'000	Between 2 and 5 years RMB'000	Over 5 years RMB'000	Total RMB'000
<b>As at 30 June 2024</b>					
Borrowings and interests	149,274	66,453	54,432	–	270,159
Trade payables	41,860	–	–	–	41,860
Other payables and accruals (excluding non-financial)	47,711	–	–	–	47,711
Lease liabilities	54,878	46,361	75,001	8,444	184,684
Other non-current liabilities	478	478	279	–	1,235
	<b>294,201</b>	<b>113,292</b>	<b>129,712</b>	<b>8,444</b>	<b>545,649</b>
<b>As at 31 December 2023</b>					
Borrowings and interests	126,822	64,188	24,133	–	215,143
Trade payables	23,482	–	–	–	23,482
Other payables and accruals (excluding non-financial)	48,818	–	–	–	48,818
Lease liabilities	42,972	43,323	92,712	13,594	192,601
Other non-current liabilities	478	478	1,433	–	2,389
	<b>242,572</b>	<b>107,989</b>	<b>118,278</b>	<b>13,594</b>	<b>482,433</b>

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 5 FINANCIAL RISK MANAGEMENT *(continued)*

#### 5.3 Fair value estimation

**(a) Fair value hierarchy**

Financial instruments carried at fair value or where fair value was disclosed can be categorised by levels of the inputs to valuation techniques used to measure fair value. The inputs are categorised into three levels within a fair value hierarchy as follows:

Level 1: The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and equity securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.

Level 2: The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives) is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities.

The Group did not change any valuation techniques in determining the level 2 and level 3 fair values.

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 5 FINANCIAL RISK MANAGEMENT (continued)

#### 5.3 Fair value estimation (continued)

##### (a) Fair value hierarchy (continued)

The following table presents the Group's assets that were measured at fair value at 30 June 2024 and 31 December 2023:

	Level 1 RMB'000	Level 2 RMB '000	Level 3 RMB'000	Total RMB'000
<b>As at 30 June 2024</b>				
Assets:				
Financial assets carried at FVPL				
– Unlisted debt instruments (Note 16)	–	–	53,926	53,926
– Unlisted equity investments (Note 16)	–	–	5,167	5,167
Financial assets carried at FVOCI				
– Bank acceptance notes (Note 13)	–	–	2,494	2,494
	–	–	61,587	61,587
	<b>Level 1 RMB'000</b>	<b>Level 2 RMB '000</b>	<b>Level 3 RMB'000</b>	<b>Total RMB'000</b>
<b>As at 31 December 2023</b>				
Assets:				
Financial assets carried at FVPL				
– Unlisted debt instruments (Note 16)	–	–	53,869	53,869
Financial assets carried at FVOCI				
– Bank acceptance notes (Note 13)	–	–	3,491	3,491
– Unlisted equity investments (Note 13)	–	–	4,772	4,772
	–	–	8,263	8,263
	–	–	62,132	62,132



## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 5 FINANCIAL RISK MANAGEMENT *(continued)*

#### 5.3 Fair value estimation *(continued)*

***(b) Valuation techniques used to determine level 3 fair values specific valuation techniques used to value financial instruments include:***

- Quoted market prices or dealer quotes for similar instruments; and
- Other techniques, such as discounted cash flow analysis, are used to determine fair value for the remaining financial instruments.

There were no changes in valuation techniques during the six months ended 30 June 2024.

The fair value of trade receivables, other receivables, long-term trade receivables, restricted cash, and cash and cash equivalents approximated their carrying amounts.

The fair value of trade payables, other payables and accruals (excluding payroll and welfare payables and other tax payables) and current borrowings approximated their carrying amounts. The fair value of non-current borrowings was disclosed in note 22.

***(c) The Group's policy is to recognize transfers into and out of fair value hierarchy levels as at the end of each reporting period. During the six months ended 30 June 2024 and 2023, there are no transfers among levels of the fair value hierarchy used in measuring the fair value of financial instruments, and also no changes in the classification of financial assets as a result of a change in the purpose or use of those assets.***

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 5 FINANCIAL RISK MANAGEMENT *(continued)*

#### 5.3 Fair value estimation *(continued)*

**(d) Fair value measurements using significant unobservable inputs (level 3)**

The following table presents the changes in level 3 instruments for the six months ended 30 June 2024 and 2023:

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
Financial assets at FVPL		
Opening Balance	53,869	50,341
Transfer from financial assets at FVOCI	4,772	–
Modification of equity investments	395	–
Fair value changes – gain to profit or loss	567	3,197
Settlement	(510)	(509)
Closing balance	59,093	53,029

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
Financial assets at FVOCI		
Opening Balance	8,263	–
Additions	4,642	5,783
Settlement	(5,639)	–
Transfer to financial assets at FVPL	(4,772)	–
Closing balance	2,494	5,783

There were no changes in valuation techniques during the periods.

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 6 REVENUE AND SEGMENT INFORMATION

#### (a) Description of segment and principal activities

During the six months ended 30 June 2024, the Group is engaged in imaging business in the Mainland China. The Group's chief operating decision maker ("CODM") has been identified as the chairman and executive directors of the Board who are responsible for allocating resources and assessing performance of the operating segment.

Management reviews the operating results of the business as one segment to make decisions about resources to be allocated. Therefore, the executive directors of the Company regards that there is only one segment which is used to make strategic decisions. Revenue and profit before income tax are the measures reported to the chairman and executive directors for the purpose of resources allocation and performance assessment.

Throughout the years, the Group has constructed, and shaped the competency in, the infrastructure supporting the operations of the imaging center and enrichment imaging services business, such as cloud platform services which represents less than 5% of the Group's total revenue.

All of the Group's business and operations are conducted in Mainland China and currently, the Group's principal market, majority of revenue, operating profit and non-current assets are derived from/located in the Mainland China. Accordingly, no geographical segment information is presented.

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 6 REVENUE AND SEGMENT INFORMATION *(continued)*

#### (b) Revenue during the six months ended 30 June 2024

An analysis of the Group's revenue by category for the six months ended 30 June 2024 and 2023 is as follows:

The revenue segment information reported to CODM for the six months ended 30 June 2024 is as follows:

		Six months ended 30 June	
		2024	2023
		RMB'000	RMB'000
	Satisfaction of performance obligation		
Imaging center services			
– Flagship imaging centers	Point in time	60,424	73,607
– Regional collaborative imaging centers	Point in time	182,677	184,654
– Specialized medical consortium imaging centers	Overtime	53,995	59,191
– Operational management imaging centers	Overtime	21,857	21,573
		318,953	339,025
Imaging solution services			
– Imaging equipment solutions	Point in time	84,552	186,464
– Equipment maintenance services	Overtime	628	–
		85,180	186,464
Rimag Cloud services			
– Cloud platform services	Overtime	5,580	4,290
– Sales of software	Point in time	4,000	–
		9,580	4,290
		413,713	529,779

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 6 REVENUE AND SEGMENT INFORMATION *(continued)*

#### (c) Contract liabilities

The Group has recognised the following contract liabilities which are the advances from customers:

	<b>As at 30 June 2024 RMB'000</b>	<b>As at 31 December 2023 RMB'000</b>
Contract liabilities related to imaging center services	3,617	3,492
Contract liabilities related to imaging solution services	14,229	5,139
Contract liabilities related to Rimag Cloud services	327	328
	<b>18,173</b>	<b>8,959</b>

The following table shows how much of the revenue recognised in the six months ended 30 June 2024 relates to carried-forward contract liabilities:

	<b>Six months ended 30 June</b>	
	<b>2024 RMB'000</b>	<b>2023 RMB'000</b>
Revenue recognised that was included in the balance of contract liabilities at the beginning of the period		
Imaging center services	96	458
Imaging solution services	4,209	54,459
Cloud platform services	17	46
	<b>4,322</b>	<b>54,963</b>



## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 7 OPERATING PROFIT

An analysis of the amounts presented as operating items in the financial information is given below.

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
Employee benefit expenses	100,487	93,385
Raw materials and trading medical equipment	81,189	184,775
Depreciation of property, plant and equipment	79,424	73,543
Listing expenses	34,454	10,487
Repair and maintenance	24,901	25,630
Marketing fees	19,960	23,686
Depreciation of right-of-use assets	18,496	14,853
Amortization of intangible assets	1,932	1,120
Losses from disposal of property, plant and equipment	69	74

### 8 FINANCE INCOME AND COSTS

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
Finance income:		
– Interest income from bank deposits	1,143	1,970
Finance costs:		
– Interest expenses on bank borrowings	(2,381)	(2,659)
– Interest expenses on other borrowings	(4,572)	(6,298)
– Finance expenses on lease liabilities	(4,116)	(3,997)
	(11,069)	(12,954)
Amount capitalized	20	326
Total finance costs	(11,049)	(12,628)
Finance costs – net	(9,906)	(10,658)

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 9 INCOME TAX EXPENSE

The amounts of income tax expense charged to profit or loss in the consolidated interim income statements represent:

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
Current income tax	11,366	19,627
Deferred income tax	(7,954)	(11,772)
	3,412	7,855

#### Global minimum top-up tax

The Group has adopted International Tax Reform – Pillar Two Model Rules – Amendments to IAS 12 upon their release on 23 May 2023. The amendments provide a temporary mandatory exception from deferred tax accounting for the top-up tax, which is effective immediately, and require new disclosures about the Pillar Two exposure from 31 December 2023. The mandatory exception applies retrospectively. However, because no new legislation to implement the top-up tax was enacted or substantively enacted at 30 June 2024 in any jurisdiction in which the Group operates and no related deferred taxes were recognised at that date, the retrospective application has no impact on the Group's condensed consolidated interim financial information.

The Company's subsidiaries established and operated in Mainland China are subject to the PRC corporate income tax at the statutory rate of 25%.

During the the six months ended 30 June 2024, according to the relevant laws and regulations promulgated by the State Administration of Taxation of the PRC, enterprises engaging in research and development activities were entitled to claim 200% of their research and development expenses incurred as tax deductible expenses when determining their assessable profits for that year (the "Super Deduction").

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 9 INCOME TAX EXPENSE *(continued)*

A reconciliation of the expected income tax calculated at the applicable corporate income tax rate and profit before income tax, with the actual corporate income tax during the the six months ended 30 June 2024 is as follow:

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
Profit before income tax	4,374	55,147
Tax calculated at applicable statutory tax rate	1,093	13,787
– Effect of preferential tax rates (a)	(2,151)	(3,123)
– Super deduction on research and development expenditure	(1,186)	(947)
– Expenses not deductible for tax purpose	5,152	4,751
– Utilisation of previously unrecognised tax losses	(3,144)	(10,565)
– Temporary differences for which no deferred income tax assets was recognised	1,423	4,259
– Share-based payment expense not recognised as deferred tax assets	112	363
– Recognition of deferred tax assets on previously unrecognised tax losses and other temporary differences	(5,803)	(10,251)
– Tax losses not recognised as deferred tax assets	7,642	8,146
– Share of result of investment in equity method	274	1,435
Income tax expense	3,412	7,855

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 9 INCOME TAX EXPENSE *(continued)*

- (a) The enterprise income tax rate applicable to the Group's entities located in Mainland China is 25% according to the Enterprise Income Tax Law of the PRC (the "EIT Law") effective on 1 January 2008 unless these subject to preferential tax rate set out below.

Each of Beijing Rimag Sunshine Medical Information Technology Co Ltd. ("Beijing Information") and Hubei Zhiying Rimag Medical Technology Co., Ltd. ("Hubei Zhiying") was qualified as a "High and New Technology Enterprise" certificate. Shicheng Rimag Sunshine Medical Imaging Co., Ltd. ("Shicheng Rimag"), Xixian Xinqu Rimag Medical Imaging Diagnosis Ltd. ("Xixian Rimag") and Shehong Jiashi Rimag Medical Imaging Diagnosis Ltd. ("Shehong Rimag") could enjoy the preferential policy of income tax for the development of the western region. According to the approval from the local taxation authority, each of Beijing Information, Hubei Zhiying, Shicheng Rimag, Xixian Rimag and Shehong Rimag was entitled to a preferential income tax rate of 15% for 2023 and the six months ended 30 June 2024.

The enterprise income tax rate applicable to the small and micro enterprises is 5% according to the EIT Law.

### 10 EARNINGS PER SHARE

#### (a) Basic

Basic earnings per share are calculated by dividing the earnings of the Group attributable to the equity holders of the Company by weighted average number of ordinary shares outstanding during the six months ended 30 June 2024.

	Six months ended 30 June	
	2024	2023
Profit attributable to the equity holders of the Company (RMB'000)	3,836	42,979
Weighted average number of ordinary shares outstanding (thousand shares)	340,858	338,496
Basic earnings per share (expressed in RMB per share)	0.011	0.127

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 10 EARNINGS PER SHARE *(continued)*

#### (b) Diluted

During the six months ended 30 June 2024 and 2023, the Group had no potential ordinary shares. Accordingly, diluted earnings per share for the six months ended 30 June 2024 and 2023 are the same as basic earnings per share for the respective periods.

### 11 PROPERTY, PLANT AND EQUIPMENT, RIGHT-OF-USE ASSETS AND INTANGIBLE ASSETS

	Property, plant and equipment	Right-of- use assets	Intangible assets
<b>Six months ended 30 June 2024</b>			
Opening net book amount as at 1 January 2024	741,122	159,904	46,214
Additions	110,755	14,336	634
Change of terms	-	(845)	-
Disposals	(2,420)	-	-
Depreciation and amortization	(79,424)	(18,496)	(1,932)
<b>Closing net book amount as at 30 June 2024</b>	<b>770,033</b>	<b>154,899</b>	<b>44,916</b>

### 12 INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

	As at 30 June 2024 RMB'000	As at 31 December 2023 RMB'000
Associates	29,662	30,760



## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 12 INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD (continued)

The movements of investments in associates accounted for using the equity method are as follows:

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
At 1 January	30,760	19,860
Addition	–	11,280
Share of post-tax profits	(1,098)	(5,585)
Deduction	–	(500)
At 30 June	29,662	25,055

The movements of investments in joint ventures accounted for using the equity method are as follows:

	Six months ended 30 June	
	2023 RMB'000	
At 1 January	6,392	
Share of post-tax profits	(155)	
Provision for impairment losses	(1,534)	
Transfer to assets classified as held for sale	(4,703)	
At 30 June	–	

### 13 FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

	As at 30 June 2024 RMB'000	As at 31 December 2023 RMB'000
	Current	
Debt investments		
– Bank acceptance notes (a)	2,494	3,491
Non current		
– Unlisted equity investments (b)	–	4,772

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 14 TRADE RECEIVABLES AND LONG-TERM TRADE RECEIVABLES

	As at 30 June 2024 RMB'000	As at 31 December 2023 RMB'000
Current		
Trade receivables		
– due from third parties	435,839	333,720
– due from related parties (Note 23(d))	406	2,666
	436,245	336,386
Less: provision for impairment	(28,981)	(27,590)
	407,264	308,796
Long-term trade receivables-current portion		
– due from third parties	26,897	25,533
– due from related parties (Note 23(d))	4,105	3,161
	31,002	28,694
Less: provision for impairment	(5,490)	(5,462)
	25,512	23,232
Non current		
Long-term trade receivables		
– due from third parties	46,155	43,086
– due from related parties (Note 23(d))	19,698	20,696
	65,853	63,782
Less: provision for impairment	(5,380)	(5,443)
	60,473	58,339
<b>Total</b>	<b>493,249</b>	<b>390,367</b>

The Group applies the simplified approach to provide for expected credit losses prescribed by IFRS 9. As at 30 June 2024 and 31 December 2023, provisions of RMB39,851,000 and RMB38,495,000 were made against the gross amounts of trade receivables and long-term trade receivables, respectively.

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 14 TRADE RECEIVABLES AND LONG-TERM TRADE RECEIVABLES (continued)

As at 30 June 2024 and 31 December 2023, the ageing analysis of the trade receivables based on the invoice date is as follows:

	<b>As at 30 June 2024 RMB'000</b>	<b>As at 31 December 2023 RMB'000</b>
Up to 1 year	380,580	294,015
1 to 2 years	42,197	29,545
2 to 3 years	8,006	12,470
Over 3 years	5,462	356
	<b>436,245</b>	<b>336,386</b>

Due to the short-term nature of the trade receivables, their carrying amounts approximated their fair values as at the balance sheet dates and were denominated in RMB.

As at 30 June 2024 and 31 December 2023, the ageing analysis of the long-term trade receivables based on the invoice date is as follows:

	<b>As at 30 June 2024 RMB'000</b>	<b>As at 31 December 2023 RMB'000</b>
Up to 1 year	18,486	40,382
1 to 2 years	41,931	17,377
2 to 3 years	13,395	30,740
Over 3 years	23,043	3,977
	<b>96,855</b>	<b>92,476</b>

The long-term trade receivables have been discounted and there is no material change on discount rate, so their carrying amounts approximated their fair values as at the balance sheet dates and were denominated in RMB.

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 15 PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

	As at 30 June 2024 RMB'000	As at 31 December 2023 RMB'000
Included in non-current assets		
<i>Other receivables</i>		
Deposits – non-current portion	29,116	14,839
Receivables from disposal of subsidiaries	8,637	9,302
Loans to a related party (Note 23(d))	2,850	3,450
Less: provision for impairment	(725)	(740)
	39,878	26,851
<i>Prepayments</i>		
Prepayments for equity investments	600	600
Prepayments for purchase of property, plant and equipment	141,683	87,970
Deductible value-added tax input	17,132	15,309
Prepayments for intangible assets	2,850	2,157
	162,265	106,036
<b>Total</b>	<b>202,143</b>	<b>132,887</b>
Included in current assets		
<i>Other receivables</i>		
Other receivables from related parties (Note 23(d))	129	236
Deposits-current portion	14,510	23,465
Advances to employees	1,091	618
Receivables from disposal of subsidiaries	840	2,360
Others	3,019	829
	19,589	27,508
Less: provision for impairment	(104)	(80)
	19,485	27,428
<i>Prepayments</i>		
Prepayment to a related party (Note 23(d))	3,200	3,240
Prepayment to suppliers	26,226	5,217
Deductible value-added tax input	3,014	23,601
Prepayment for listing expenses	1,226	13,011
Prepaid expenses	17,749	13,590
	51,415	58,659
<b>Total</b>	<b>70,900</b>	<b>86,087</b>

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 16 FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

	As at 30 June 2024 RMB'000	As at 31 December 2023 RMB'000
Non-current		
– Unlisted debt instruments (Note 5.3(a))	53,926	53,869
– Unlisted equity investments (Note 5.3(a))	5,167	–
	<b>59,093</b>	<b>53,869</b>

### 17 SHARE CAPITAL

	Number of ordinary shares of RMB1.00 each	Share capital RMB'000
<b>Issued and fully paid:</b>		
<b>As at 1 January 2023 and 31 December 2023</b>	338,495,832	338,496
– Issue of shares pursuant to the Listing (a)	17,816,000	17,816
<b>As at 30 June 2024</b>	<b>356,311,832</b>	<b>356,312</b>

- (a) On 7 June 2024, the Company issued 17,816,000 ordinary shares at HK\$14.98 per share, and raised gross proceeds of approximately HK\$266,883,680. The Company's shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited on 7 June 2024. The gross proceeds are capitalized as share capital and share premium accordingly.



## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 18 RESERVES

The following table shows a breakdown of the balance sheet line items “reserves” and its movements during the respective years. A description of the nature and purpose of each reserve is provided below the table.

	Share premium RMB'000	Capital reserves RMB'000	Financial assets at FVOCI RMB'000	Share- based payment reserves RMB'000	Total RMB'000
<b>As at 1 January 2024</b>	1,136,018	(30,197)	3,182	292,971	1,401,974
Share-based payment	–	–	–	466	466
Issue of shares pursuant to the Listing	225,147	–	–	–	225,147
Listing expenses capitalised upon listing	(15,574)	–	–	–	(15,574)
Financial assets at FVOCI	–	–	(2)	–	(2)
<b>As at 30 June 2024</b>	<b>1,345,591</b>	<b>(30,197)</b>	<b>3,180</b>	<b>293,437</b>	<b>1,612,011</b>
<b>As at 1 January 2023</b>	1,136,018	–	–	290,414	1,426,432
Share-based payment	–	–	–	2,557	2,557
Transactions with non-controlling interests (i)	–	(30,197)	–	–	(30,197)
Financial assets at FVOCI	–	–	3,182	–	3,182
<b>As at 31 December 2023</b>	<b>1,136,018</b>	<b>(30,197)</b>	<b>3,182</b>	<b>292,971</b>	<b>1,401,974</b>

- (i) Note: The Company entered into a share transfer agreement in December 2023 for acquisition of remaining 49% equity interest in a subsidiary Hainan Rimag Sunshine Medical Investment Management Co. Ltd. (“Hainan Rimag”) at a consideration of RMB15,900,000. The Company already paid RMB14,310,000 in 2023 while the completion of the transaction was still subject to certain financial performance conditions in late 2024 which is not under the Company’s control. Hence the full consideration for purchasing non-controlling shareholdings is debited to equity with the remaining unpaid consideration of RMB1,590,000, which is also subject to certain financial performance conditions in 2024, recorded in other payables and accruals as at 31 December 2023.

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 19 SHARE-BASED PAYMENTS

Expenses arising from equity-settled share-based payments transactions were as follows:

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
Share Incentive Plan (a)	472	1,501

(a) Share-based payments expenses recognised for the six months ended 30 June 2024 and 2023 were as follows:

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
Administrative expenses	472	1,490
Selling and distribution expenses	–	8
Cost of sales	–	1
Research and development expenses	–	2
	472	1,501

### 20 DIVIDEND

No dividends have been paid or declared by the Company during each of the six months ended 30 June 2024 and 2023.

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 21 TRADE PAYABLES

	<b>As at 30 June 2024 RMB'000</b>	<b>As at 31 December 2023 RMB'000</b>
Trade payables -Third parties	41,860	23,482

The ageing analysis of trade payable as at 30 June 2024 and 31 December 2023 based on invoice date was as follows:

	<b>As at 30 June 2024 RMB'000</b>	<b>As at 31 December 2023 RMB'000</b>
Up to 1 year	38,325	20,018
1-2 years	3,220	2,692
Over 2 year	315	772
	41,860	23,482

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 22 BORROWINGS

	As at 30 June 2024 RMB'000	As at 31 December 2023 RMB'000
Non-current:		
Long-term bank borrowings, secured	56,993	55,904
Long-term bank borrowings, unsecured	10,000	–
Loans from financial leasing companies, secured	164,956	130,302
Less: Current portion of long-term bank borrowings, secured	(35,351)	(28,324)
Current portion of long-term bank borrowings, unsecured	(200)	–
Current portion of loans from financial leasing companies, secured	(78,170)	(72,916)
	118,228	84,966
Current:		
Short-term bank borrowings, secured	7,880	8,280
Short-term bank borrowings, unsecured	25,000	15,000
Current portion of long-term bank borrowings, secured	35,351	28,324
Current portion of long-term bank borrowings, unsecured	200	–
Current portion of loans from financial leasing companies, secured	78,170	72,916
Loans from a third party, unsecured	547	522
	147,148	125,042
<b>Total borrowings</b>	<b>265,376</b>	<b>210,008</b>

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 22 BORROWINGS (continued)

- (a) The Group's borrowings as at the balance sheet dates during the six months ended 30 June 2024 were repayable as follows:

	As at 30 June 2024		As at 31 December 2023	
	Bank Borrowings	Others	Bank Borrowings	Others
Up to 1 year	68,431	78,717	51,604	73,438
Between 1 and 2 years	29,181	34,852	22,328	39,107
Between 2 and 5 years	2,261	51,934	5,252	18,279
<b>Total</b>	<b>99,873</b>	<b>165,503</b>	<b>79,184</b>	<b>130,824</b>

- (b) The carrying amounts of the Group's borrowings are denominated in the following currencies:

	As at 30 June 2024		As at 31 December 2023	
	Bank Borrowings	Others	Bank Borrowings	Others
RMB	99,873	165,503	79,184	130,824

- (c) The weighted average effective interest rates at each balance sheet date were as follows:

	Six month ended 30 June	
	2024	2023
Bank borrowings	5.87%	4.92%
Loans from financial leasing companies	7.88%	9.63%
Loans from a third party, unsecured	12.00%	–



## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 22 BORROWINGS (*continued*)

#### (d) Other disclosures

(i) **Fair values**

The carrying amounts for the majority of the borrowings approximated their fair values as they were carried at floating interest rates.

(ii) **Risk exposures**

Details of the Group's exposure to risks arising from current and non-current borrowings are set out in Note 5.1 and Note 5.2.

### 23 RELATED PARTY TRANSACTIONS

Parties are considered to be related in one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operation decisions. Parties are also considered to be related if they are subject to common control.

The following is a summary of the significant transactions carried out between the Group and its related parties in the ordinary course of business during the six months ended 30 June 2024, and balances arising from related party transactions as at 30 June 2024 and 31 December 2023 respectively.

The major related parties that had transactions and balances with the Group were as follows:

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 23 RELATED PARTY TRANSACTIONS (continued)

#### (a) Related parties of the Company and the Group

Name of related parties	Relationship
Hanji Health Management (Shanghai) Co., Ltd. (漢吉健康管理(上海)有限公司)	Associate
Shanghai Zhengying Medical Imaging Diagnosis Center Co., Ltd. (上海正影醫學影像診斷中心有限公司)	Associate
Ningde Jiaotou Yimai Sunshine Medical Imaging Diagnosis Center Co., Ltd. (寧德市交投一脈陽光醫學影像 診斷中心有限公司)	Associate
Beijing Yimai Wanfang Clinic Co., Ltd. (北京一脈萬方診所有限公司)	Associate
Shanghai Yimai Xinyun Medical Technology Co., Ltd. (上海一脈心雲醫療科技有限公司)	Associate
Shanghai Shihe Intelligent Electronic Technology Co., Ltd. (上海實和智能電子科技有限公司)(Note)	Joint venture
Wuhan Rong Commune Medical Equipment Co., Ltd. (武漢融公社醫療器械有限公司)	A company controlled by a Director

Note: According to the Articles of Association of Shanghai Shihe Intelligent Electronic Technology Co., Ltd., all resolutions must be unanimously passed by all shareholders, and none of the participating parties has unilateral control over the economic activity of the jointly controlled entity, which is thus accounted for the investment as an investment in joint ventures. In September 2023, the Company entered into a share transfer agreement that the Company sell the 20% equity interests to a third party. The Company will receive a fixed amount of RMB5,000,000 over one year on monthly basis. The transaction will be completed after all the payments are settled. As at 30 June 2024 and 31 December 2023, it was accounted for as asset classified held for sale.

The following is a summary of the significant transactions carried out between the Group and its related parties in the ordinary course of business during the six months ended 30 June 2024, and balances arising from related party transactions as at the respective balance sheet dates.

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 23 RELATED PARTY TRANSACTIONS (continued)

#### (b) Transactions with related parties

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
<b>Sales of services and goods</b>		
Ningde Jiaotou Yimai Sunshine Medical Imaging Diagnosis Center Co., Ltd.	828	–
Beijing Yimai Wanfang Clinic Co., Ltd.	317	652
	1,145	652
<b>Purchase of services and products</b>		
Hanji Health Management (Shanghai) Co., Ltd.	2,314	–
Shanghai Shihe Intelligent Electronic Technology Co., Ltd.	140	85
Shanghai Yimai Xinyun Medical Technology Co., Ltd.	121	–
Shanghai Zhengying Medical Imaging Diagnosis Center Co., Ltd.	115	–
	2,690	85

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 23 RELATED PARTY TRANSACTIONS *(continued)*

#### (c) Key management compensation

Key management includes Directors (executive and non-executive), chief executive officer, the Company secretary, and the executive president of imaging hospital. The compensation paid or payable to key management for employee services is as follows:

	Six months ended 30 June	
	2024 RMB'000	2023 RMB'000
– Salaries, wages and bonuses	2,037	1,591
– Pension costs-defined contribution plans	167	40
– Housing fund, medical insurance and other social insurance	546	32
– Share-based payments expenses	–	14
	2,750	1,677

For the six months ended 30 June 2024 and 2023, the salaries, bonus and other welfares disclosed above include RMB367,000 and RMB222,000 payables which were unpaid as at period end and are included in other payables and accruals.

## Notes to the Condensed Consolidated Interim Financial Information

For the six months ended 30 June 2024

### 23 RELATED PARTY TRANSACTIONS (continued)

#### (d) Balances with related parties

	As at 30 June 2024 RMB'000	As at 31 December 2023 RMB'000
<b>Trade receivables and long-term trade receivables</b>		
Shanghai Zhengying Medical Imaging Diagnosis Center Co., Ltd.	23,605	23,907
Beijing Yimai Wanfang Clinic Co., Ltd.	604	409
Ningde Jiaotou Yimai Sunshine Medical Imaging Diagnosis Center Co., Ltd.	–	2,207
Less: allowance for expected credit losses	(820)	(848)
	23,389	25,675
<b>Other receivable and prepayments</b>		
– <i>Other receivable</i>		
Shanghai Zhengying Medical Imaging Diagnosis Center Co., Ltd.	2,850	3,450
Ningde Jiaotou Yimai Sunshine Medical Imaging Diagnosis Center Co., Ltd.	129	236
– <i>Prepayments</i>		
Hanji Health Management (Shanghai) Co., Ltd.	3,200	3,200
Shanghai Zhengying Medical Imaging Diagnosis Center Co., Ltd.	–	40
Less: allowance for expected credit losses	(11)	(12)
	6,168	6,914
<b>Other payable and accruals</b>		
Wuhan Rong Commune Medical Equipment Co., Ltd.	689	689
Shanghai Zhengying Medical Imaging Diagnosis Center Co., Ltd.	16	–
Shanghai Shihe Intelligent Electronic Technology Co., Ltd.	–	13
	705	702
<b>Contract liability</b>		
Ningde Jiaotou Yimai Sunshine Medical Imaging Diagnosis Center Co., Ltd.	7,880	–



## Definitions

“associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Audit Committee”	the audit committee of the Board
“Board of Directors” or “Board”	the board of Directors
“China” or “PRC”	the People’s Republic of China, which for the purpose of this interim report and for geographical reference only, excludes Hong Kong, Macau and Taiwan
“Company” or “our Company”	Jiangxi Rimag Group Co., Ltd. (江西一脈陽光集團股份有限公司), a company initially established under the laws of the PRC on October 30, 2014 as a joint stock company with limited liability, subsequently converted into a limited liability company on July 15, 2016 and further converted into a joint stock company with limited liability in the PRC on June 30, 2021 and the H Shares of which are listed on the Stock Exchange (stock code: 2522) and which includes its subsidiaries (from time to time) where the context so requires
“Corporate Governance Code”	the “Corporate Governance Code” as set out in Appendix C1 to the Listing Rules
“Director(s)”	the director(s) of the Company
“Global Offering”	the global offering of an aggregate of 17,816,000 H Shares by the Company, details of which are set out in the Prospectus
“Group”, “we” or “us”	our Company and its subsidiaries (or our Company and any one or more of its subsidiaries, as the context may require)
“H Share(s)”	overseas listed foreign ordinary share(s) in the share capital of our Company with nominal value of RMB1.00 each, which are listed and traded on the Stock Exchange
“HK\$”	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC

## Definitions

“Interim Results Announcement”	the interim results announcement for the six months ended June 30, 2024 of the Company dated August 27, 2024
“Listing Date”	June 7, 2024
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
“Main Board”	the stock market (excluding the option market) operated by the Stock Exchange, which is independent from and operated in parallel with Growth Enterprise Market of the Stock Exchange
“Model Code”	the “Model Code for Securities Transactions by Directors of Listed Issuers” set out in Appendix C3 to the Listing Rules
“Nanchang Rimag”	Nanchang Rimag Sunshine Enterprise Management Center (Limited Partnership) (南昌一脈陽光企業管理中心(有限合夥)), a limited liability partnership established under the laws of the PRC on March 28, 2016 as an employee shareholding platform of the Company
“Prospectus”	the prospectus issued by the Company dated May 30, 2024
“Reporting Period”	the six months ended June 30, 2024
“RMB”	Renminbi, the lawful currency of the PRC
“second half of 2023”	the six months ended December 31, 2023
“Share(s)”	ordinary shares in the share capital of our Company with a nominal value of RMB1.00 each, including unlisted shares and H Shares
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed thereto under the Listing Rules
“%”	per cent